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1. Introduction
Sarcoidosis is a systemic granulomatous disease of unknown aetiology, which can affect
virtually any organ and is thus characterised by a variable clinical presentation and course.
The disease is generally considered to be a T helper-1 (TH1) type of reaction, although TH2 and
TH17 features have also been identified. Approximately 90% of patients demonstrate disease
involvement of the lungs and thoracic lymph nodes and although sarcoidosis is usually
subacute and self-limiting, progressive inflammation can lead to pulmonary fibrosis and
death. Despite these features, there is currently no definitive single laboratory investigation
used to identify sarcoidosis, indicating the need for improved understanding of the immuno‐
pathogenesis and identification of disease-specific biomarkers. Currently, sarcoidosis is
generally a diagnosis of exclusion that is best confirmed by clinical and radiological findings
and tissue biopsies revealing non-caseating granulomas in the absence of known granuloma‐
genic agents. Laboratory testing is nonetheless beneficial in further supporting a diagnosis of
sarcoidosis and assessing disease severity.
In this chapter, we focus on the laboratory and immunological testing used in sarcoidosis,
including biomarkers that have been proposed as measures of the immunological response,
as well as cellular markers present in blood and bronchoalveolar lavage. Comparisons will
also be made with older immunological investigations including the Kveim-Siltzbach test and
recent evidence of potential sarcoid antigens. Novel methods of sampling disease biomarkers,
including the technique of exhaled breath analysis will be explored. Immunological testing
and measurement of various biomarkers in body tissues has been a useful research tool in
understanding sarcoid pathophysiology. There may be a useful role for some of these labora‐
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tory investigations as future clinical tools, improving diagnostic sensitivity and identifying
novel targets for treatment [1].
2. Serum chemistries and other initial investigations
The diagnosis of sarcoidosis is based on a compatible clinical and radiological picture,
histological evidence of non-caseating granulomas and exclusion of other diseases which show
a similar clinical or histological picture [2]. The clinical, radiological and histological features
of sarcoidosis are discussed elsewhere in this book. The recommended initial clinical and
laboratory investigations for a patient suspected of having sarcoidosis are listed in Table 1.
The rationale for these investigations is to detect frequent manifestations of the disease, as well
as identification of serious, although rare complications of sarcoidosis such as cardiac disease.
Routine testing Additional testing
Peripheral blood Peripheral blood counts: white blood cells, red blood
cells, platelets
Angiotensin-converting enzyme (ACE)
Serum chemistry: calcium, creatinine, renal function,
liver enzymes, CRP, ESR
Glucose
Radiological
procedures
Chest radiography High resolution CT scan
Pulmonary function
studies
Spirometry Lung volumes and diffusing capacity of
carbon monoxide. Six-minute walk
with oximetry
Other testing Urinalysis 24-hour urinary calcium
Electrocardiogram (ECG)
Routine ophthalmologic examination
Tuberculin skin test IFN-γ release assays
Other tests depending on clinical manifestations and
suspicion of specific organ involvement
Table 1. Recommended initial clinical and laboratory investigations of patients with suspected sarcoidosis. Source:
reference [11].
Simple baseline blood tests are useful to identify the presence and severity of specific organ
involvement, including hepatic or renal impairment. Peripheral blood lymphopenia is a
common finding in patients with sarcoidosis [3], as the activated T cells accumulate at the
sites of granulomatous inflammation [4]. This may contribute to the systemic immunological
abnormalities observed in sarcoidosis, with exaggerated local immune responses, but sup‐
pressed delayed-type hypersensitivity (DTH) skin tests and peripheral blood immune re‐
sponses [5-7]. Other haematological abnormalities such as neutropenia or auto-immune
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haemolytic anaemia and/or thrombocytopenia appear very infrequently [8]. Approximately
10-20% of all patients with sarcoidosis have elevated serum aminotransferase and alkaline
phosphatase levels [2, 9]. A cholestatic picture of hepatic impairment from granulomatous
cholangitis can also occur with a syndrome of pruritis and jaundice. Hepatic failure or portal
hypertension can also develop, although liver involvement is usually clinically silent [10].
Although renal disease is uncommon, increased serum creatinine and urea levels can reflect
renal impairment related to chronic hypercalcemia, hypercalciuria, nephrolithiasis, nephro‐
calcinosis or granulomatous interstitial nephritis [12-14]. Hypercalciuria is observed in over
40% of patients with sarcoidosis and hypercalcemia in 5-10% of cases and occurs mainly in
males over 40 years of age [8, 10]. Hypercalcemia and hypercalciuria in sarcoidosis are
attributed to increased levels of serum 1,25-dihydroxyvitamin D3 (also known as calcitriol),
which increases serum calcium levels via increased intestinal calcium absorption and osteo‐
clastic bone resorption. The kidney is normally the only organ that can hydroxylate vitamin
D3 to its biologically active form of 1,25-dihydroxyvitamin D3. Sarcoid macrophages have also
been shown to posses the enzyme 25-hydroxyvitamin D3-1α-hydroxylase, which converts 25-
hydroxyvitamin D3 to its active form, which is produced in excess in sarcoid granulomas [12,
15, 16] and is not inhibited by normal negative feedback from hypercalcemia [15]. Alveolar
macrophages have been shown to be the source of excess calcitriol in sarcoidosis, through
elevated mRNA expression of the 25-hydroxyvitamin D3-1α-hydroxylase gene [17]. It has been
found that even anephric patients with sarcoidosis can develop hypercalcemia, through this
alternative extrarenal source of the hydroxylase enzyme to create calcitriol [18]. Hypercalciuria
is common in sarcoidosis and results from an increased calcium load filtered at the glomerulus,
along with suppression of parathyroid hormone secretion by calcitriol, which diminishes renal
tubular calcium reabsorption [12]. In an evaluation of 736 newly diagnosed sarcoidosis patients
in the United States, 3.7% of all patients had abnormalities with calcium metabolism, with
hypercalcaemia being more common in Caucasians than African Americans [9]. Therefore
monitoring of serum calcium, as well as 24-hour urinary excretion of calcium should be
measured in all patients with sarcoidosis [12]. As chronic hypercalcemia is a common and
treatable cause of renal failure in sarcoidosis, it is important not to miss this complication.
Hypercalcemia and increased calcitriol have also been described in infectious granulomatous
disorders [19-22], again resulting from abnormal extrarenal metabolism of vitamin D3.
The erythrocyte sedimentation rate (ESR) and the acute phase reactant C-reactive protein
(CRP) have been used as nonspecific markers of inflammation in a wide variety of diseases.
They are simple initial investigations for assessing the severity of systemic inflammation. In
sarcoidosis very high levels of ESR and CRP have been observed in some patients with active
disease [23]. The ESR level is more likely to be increased in patients with arthritis [24] and in
those with erythema nodosum [25] than for other manifestations of the disease. CRP has been
found to be associated with fatigue in sarcoidosis [26]. Levels of CRP are generally lower in
patients with sarcoidosis compared with tuberculosis [27] and CRP measurement is less
sensitive and specific for sarcoidosis compared to ACE [28].
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3. Lymphocytic aspects, cytokines and chemokines in sarcoidosis
Sarcoidosis is characterised by an “immune paradox” of exaggerated TH1 lymphocyte
processes causing localised inflammation, although there is peripheral anergy to common
antigens [29]. In patients with sarcoidosis total numbers of peripheral blood lymphocytes are
normal or slightly reduced, but at disease sites there is a marked increase characterised by
ratios of CD4+ to CD8+ T-cells ranging between 3.5:1 to 15:1 in about 50% of cases, compared
to normal ratios of 2:1 [1, 30]. Peripheral anergy in sarcoidosis as displayed by suppression of
delayed-type hypersensitivity (DTH) responses may be explained by expansion of a subgroup
of CD25bright FOXP3+ regulatory T-cells (Treg) in active sarcoidosis [6, 29]. The initial stimulus
which induces local inflammation arises when an unknown insoluble antigen is presented on
MHC class II molecules to CD4+ TH1 lymphocytes. This leads to exaggerated activation and
clonal proliferation of these lymphocytes, which produce increased amounts of interleukin-2
(IL-2), a local growth, survival and differentiation factor for T-lymphocytes [31]. These
lymphocytes also release interferon-γ, together with cytokines and chemokines produced by
mononuclear phagocytes (namely TNF-α, IL-12, IL-18, monocyte chemotactic protein-1
(MCP-1), macrophage inflammatory protein-1α (MIP1α)) into the local milieu [1, 31), which
leads to activation of blood monocytes that form non-caseating granulomas. The likely
outcomes following granuloma formation are either resolution or fibrosis, which may be
dependent on predominance of TH1 or TH2 T cell responses respectively.
TH1 cytokines including IFN-γ promote granulomatous inflammation and inhibit fibrosis
development, with Bronchoalveolar lavage (BAL) fluid IFN-γ levels being inversely related to
progression to pulmonary fibrosis and are higher than BAL IFN-γ levels in healthy controls
[1]. TH2 type cytokines (e.g. IL-4, IL-5, IL-10, IL-13) and macrophage derived factors including
fibronectin, platelet-derived growth factor, insulin-like growth factor-1 (IGF-1) and trans‐
forming growth factor-β1 (TGF-β1) promote fibroblast proliferation leading to either healing
or progressive fibrosis [10]. The IL-17 producing TH17 cells, considered developmentally
distinct from TH1 and TH2 cells, have also recently been implicated in the pathogenesis of
sarcoidosis. TH17 cells are associated with autoimmune disease processes, granuloma forma‐
tion and have a role in host defence against extracellular pathogens [32]. Recent findings from
flow cytometry indicate that there are increased IL-17+ and IL-23R+ peripheral blood and BAL
CD4+ T-cells from patients with active sarcoidosis compared to those with inactive disease or
healthy controls and increased IL-17 and IL-23R expression in lung and lymph node specimens
[33]. This was also confirmed with an increased presence of IL-17A+, IL-17A+ IFN-γ+ and IL-17A
+ IL-4+ memory T-cells in peripheral blood and BAL of patients with sarcoidosis and increased
IL-22+ cells in granuloma containing biopsies [34]. Gene profiling studies using sarcoid skin
biopsies have also showed upregulated TH1 and TH17 gene expression along with increased
IL-23 and IL-23R expression in patients with sarcoidosis compared with healthy volunteers
[35]. Other groups found conflicting results using enzyme-linked immunospot (ELISPOT)
assays [36], as well as finding reduced IL-17A gene expression in BAL CD4+ T-cells in patients
with Löfgren’s syndrome compared to controls [37]. These data indicate that the TH17 subset
may have a systemic role in active non-Löfgren’s disease and may be involved in disease
progression [1].
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Some of the principal cytokines and chemokines involved in sarcoidosis are summarised in
Table 3. Sarcoidosis is also characterised by a polyclonal hypergammaglobulinaemia and
circulating immune complexes, which is observed in 20-80% of cases. This may result from
non-specific B-cell activation by activated T-helper lymphocytes in lymphoid organs [38].
Monocytes/macrophages Lymphocytes
ACE IL-2, IFN-γ
Lysozyme TNF-α, TNF-β
Neopterin TGF-β
Chitotriosidase IL-6, IL-10, IL-12, IL-17
TGF-β CCL-5
TNF-α, IL1-1β, IL-12, IL-18 GM-CSF
CCL2, CCL3, CCL4,
CCL10, CCL18
CXCL10
GM-CSF
Table 2. Summary of key cytokines, chemokines and factors expressed by activated lymphocytes and macrophages in
the pathogenesis of sarcoidosis, which have be measured in biological samples. Abbreviations: CCL: C-C motif ligand;
CXCL: C-X-C motif ligand; GM-CSF: granulocyte macrophage colony stimulating factor.
3.1. Lymphocyte markers: Soluble IL-2 receptor (sIL-2R)
Lung T-cells from patients with pulmonary sarcoidosis express both early and late activation
cell surface markers, with IL-2R (CD25) being one of the most widely studied. The soluble form
of the IL-2 receptor (sIL-2R) is a T-cell receptor for IL-2, which is used to monitor graft rejection
after solid organ transplantation and can be elevated in a number of conditions including
infection and autoimmune disease [39]. Its concentrations are elevated and easily detectable
in the serum and BAL of patients with sarcoidosis and arises as a result of increased numbers
and enhanced activation of macrophages and T-cells from granulomatous inflammation [40,
41]. In some studies, elevated serum sIL-2R falls during therapy or with spontaneous remission
[42, 43]. Recent studies indicate that sIL-2R may have prognostic value as a marker of disease
activity as the levels are significantly higher in patients with active sarcoidosis compared with
inactive disease, correlating with BAL CD4+ T-cell numbers [41, 44]. Patients with extrapul‐
monary sarcoidosis excluding Löfgren’s syndrome have also demonstrated greater serum
sIL-2R levels compared to those with isolated pulmonary involvement [41], with sIL-2R
appearing to be an independent marker for worse disease. sIL-2R has been compared with
serum CRP, serum amyloid A and ACE activity indicating that only sIL-2R was predictive of
sarcoidosis severity and could be used for patient follow-up [23].
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3.2. β2-microglobulin
β2-microglobulin is a low molecular weight protein and a marker of lymphocyte activation. It
has been described in a variety of infectious, inflammatory and neoplastic diseases and is used
to monitor patients with lymphoma. Various studies have identified that approximately 25%
of patients with sarcoidosis have elevated serum β2-microglobulin concentrations [30, 45, 46].
Initial findings in sarcoidosis patients indicated that the levels were elevated at the time of
diagnosis, rose during relapse and fell with corticosteroid therapy [47]. In a study of 107
patients with sarcoidosis, β2-microglobulin levels were found to correlate with granuloma
formation in the initial phases, whilst ACE activity reflected later phases. It was also noted that
in patients with acute sarcoidosis and erythema nodosum, β2-microglobulin was elevated and
ACE was usually normal [46]. Another study of 132 sarcoidosis patients did not find an
association between β2-microglobulin and ACE [45], indicating that lymphocyte and macro‐
phage activation are not always concurrently present. This is one limitation of this marker in
that it only assesses lymphocyte activation, compared to sIL-2R which reflects both macro‐
phage and lymphocyte activation. β2-microglobulin concentrations have also been measured
in the cerebrospinal fluid (CSF) and were found to be elevated in 68% of patients with
neurosarcoidosis, although it was not elevated in patients who did not have neurological
involvement [48]. As it has low specificity and sensitivity, serum β2-microglobulin has limited
use in clinical practice.
4. Immunological studies of alveolitis: BAL and induced sputum
BAL fluid analysis is a useful investigation for the diagnosis of pulmonary sarcoidosis by
detecting a lymphocytosis with elevated ratios of CD4+/CD8+ cells, typically >3.5:1, in the
absence of other causes [1]. BAL lymphocytosis with elevated CD4/CD8 ratios, normal
percentages of eosinophils and neutrophils and the absence of plasma cells suggest a diagnosis
of sarcoidosis. Cellular analysis of T-lymphocyte subsets and cytokine levels from BAL fluid
and peripheral blood using flow cytometry have been compared and can provide useful
diagnostic information on sarcoid alveolitis. Costabel et al. reported on the clinical utility of
BAL CD4/CD8 ratios in the diagnosis of sarcoidosis. Ratios greater than 3.5 have a sensitivity
of 53%, specificity of 94%, positive predictive value of 76% and a negative predictive value of
85% for sarcoidosis, and with higher ratios the specificity nearly reaches 100% [49]. For
individual cases, CD4/CD8 ratios may not always be useful as some patients may have either
decreased, normal or increased ratios, or in rare cases may present with a CD8 alveolitis, such
as in sarcoid patients with HIV-1 infection [50].
Ex vivo studies in patients with sarcoidosis with flow cytometry identified greater activation
of non-stimulated BAL CD4+ and CD8+ T cells when compared with peripheral blood
lymphocytes [51], demonstrating compartmentalisation of the immune response. A large
number of BAL lymphocytes from patients with active sarcoidosis express cell surface
activation markers including CD26, CD54, CD69, CD95 and HLA-DR [51, 52]. CD4+/HLA-DR
+ T-cells spontaneously release IL-2. Some investigators identified the possibility of using the
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number of CD4+/HLA-DR+ cells for evaluating the activation state of the IL-2 system and
defining different phases of sarcoidosis, as numbers decrease in inactive disease [53]. It is also
interesting to note studies with BAL fluid from sarcoidosis patients who have the HLA-
DRB1*0301-positive genotype predominantly express the Vα2.3 (AV2S3+) T-cell receptor. The
increase in AV2S3+ CD4+ T-cells may be very significant during acute disease in these patients
and constitute more than 30% of BAL T-cells, as well as expressing cell surface activation
markers including CD26, CD28, CD69 and HLA-DR [54], indicating acute clonal expansion
and proliferation in response to inciting antigen(s) [55].
Intracellular cytokine expression has been compared in activated BAL and peripheral blood
lymphocytes using non-specific lymphocyte mitogens in patients with sarcoidosis and healthy
controls. Some studies suggest compartmentalised shifts in the TH1/TH2 cytokine balance
modulate granulomatous lung inflammation and its evolution towards disease resolution or
development of pulmonary fibrosis [1]. BAL T-cells from patients with pulmonary sarcoidosis
show a dominant TH1 cytokine expression, with elevated mRNA and protein levels of IFN-γ
and IL-2, as well as TNF-α but not IL-4 [52, 56-59]. Additionally, BAL alveolar macrophages
have been shown to be important regulators of the TH1 response by producing IL-12 and IL-18,
which stimulate IFN-γ production and differentiation of naïve T-cells into a TH1 phenotype
[60]. Following stimulation, significantly more BAL CD4+ cells express TH1 receptors CXCR3,
CCR5, IL-12R and IL-18R, but fewer TH2 chemokine receptors (CXCR4, CCR4) when compared
with paired peripheral blood CD4+ T-cells [61]. A recent study of 52 sarcoidosis patients and
21 healthy controls identified that circulating levels of the TH1 chemokine IFN-inducible
protein (IP-10/CXCL10) and the TH2 chemokine CCL17 were both elevated in the serum of
patients compared to controls [62]. They additionally found that there was significantly greater
IP-10 production by BAL cells in patients with active sarcoidosis compared to controls but no
difference in BAL CCL17 levels. Interestingly, increased numbers of CD4+ CD25bright FOXP3+
Treg cells have been identified in the peripheral blood and BAL fluid of patients with active
sarcoidosis. These cells exhibit powerful anti-proliferative ability but are unable to completely
down-regulate production of pro-inflammatory cytokines including IFN-γ and TNF-α, thus
allowing granuloma formation [6, 29]. Further investigations are needed to evaluate the
TH1/TH2/TH17 network in sarcoidosis, during different disease stages and the regulatory
mechanisms which may be involved.
A CD4+ IFN-γ+ T-cell alveolitis with elevated ratios of CD4+/CD8+ T-cells has also been
confirmed in patients with active pulmonary disease using induced sputum, a relatively less-
invasive technique compared with BAL [63]. A strong correlation has been confirmed between
T-cell subsets in BAL fluid and induced sputum in patients with sarcoidosis, although the
proportion of alveolar macrophages was significantly lower in induced sputum [64]. Increased
levels of regulatory CD4+ CD25bright CD127low T-cells have also been confirmed in induced
sputum of patients with active pulmonary sarcoidosis [65]. This indicates that induced sputum
may be a less invasive yet useful method of investigating the immunology of pulmonary
disorders.
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5. Exclusion of granulomatous diseases mimicking sarcoidosis
There has been an increase in the armamentarium of specific immunological and microbio‐
logical tests to identify granulomatous disorders which would have previously been mistak‐
enly labelled as sarcoidosis. Table 3 lists common granulomatous conditions, some of which
need to be considered in the differential diagnosis of a patient with suspected sarcoidosis.
Some investigations which can be used depending on the clinical context to identify other
causes of granulomatous inflammation include: the beryllium lymphocyte proliferation test,
which can be performed on peripheral blood or BAL mononuclear cells to test for chronic
beryllium disease [66], tests for anti-neutrophil cytoplasmic antibodies for Wegener’s granu‐
lomatosis and related vasculitides, anti-mitochondrial antibodies for primary biliary cirrhosis
and serological and culture methods for infectious diseases. Investigations of special interest
are discussed in detail below.
5.1. Tuberculin skin test, delayed-type hypersensitivity and interferon-γ release assays
Although patients with sarcoidosis exhibit an exaggerated TH1 immune response at sites of
disease, they commonly have depressed peripheral blood responses to common antigens [5,
67], are unresponsive to vaccinations [7, 68] and demonstrate suppression of DTH to tuber‐
culin. Impaired DTH is a clinical feature of sarcoidosis, with skin anergy demonstrated to recall
antigens and polyclonal mitogens including mumps virus, Trichophyton, Candida, streptoki‐
nase/streptodornase, dinitrochlorobenzene [5, 69-71] but not phytohaemagglutinin (PHA)
[72]. Similarly, patients exhibit cutaneous anergy to the tuberculin skin test, which is consid‐
ered as part of the diagnostic criteria for sarcoidosis [73]. It has also been determined that in
populations with a high incidence of tuberculosis, the presence of tuberculin skin test anergy
is less reliable in making a diagnosis of sarcoidosis, compared with the use of interferon-γ
release assays (IGRA). In these populations and in patients with immune deficiencies, IGRA
is more accurate in unmasking an actual case of latent tuberculosis infection, in patients who
were labelled as having “sarcoidosis” [74, 75]. IGRAs have a higher sensitivity and specificity
for detecting Mycobacterium tuberculosis (MTB) than the conventional tuberculin skin test, as
they utilise antigens specific for MTB complex [76, 77]. The recent QuantiFERON-TB Gold
IGRA is based on the principle that T-cells from a whole blood sample of a patient previously
exposed to specific MTB complex antigens, including Culture Filtrate Protein-10 (CFP-10),
Early Secretory Antigenic Target-6 (ESAT-6) and purified protein-derivative (PPD) will
produce IFN-γ, which is measured using enzyme-linked immunosorbent assay (ELISA). These
proteins are absent from BCG strains and most non-tuberculous mycobacteria, hence provid‐
ing specific testing for M. tuberculosis. Screening for prior tuberculosis infection, with a detailed
history, tuberculin skin testing or use of IGRAs is also required prior to starting anti-TNF
therapy, as these drugs are associated with serious infection risk from reactivation of latent
tuberculosis [78].
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Disease associations Characterisation
Infectious Mycobacteria: tuberculosis, leprosy, Bacillus Calmette-Guérin (BCG) and atypical
mycobacteria
Propionibacterium acnes, P. granulosum; Borrelia burgdorferi; Yersinia spp.;Brucella spp.,
Cat-Scratch disease (Bartonella henselae)
Protozoal: Toxoplasmosis, Leishmaniasis
Spirochaetes: Treponema pallidum (secondary or tertiary syphilis), T. carateum, T.
pertunue (yaws)
Invasive fungal infections: histoplasmosis, sporotrichosis, aspergillosis, cryptococcosis,
blastomycosis, coccidioidomycosis
Pseudomycoses: actinomycoses, nocardiosis, botryomycosis
Herpes simplex virus, Epstein-Barr virus, cytomegalovirus
Helminth infections: Schistosomiasis, Ascaris lumbricoides
Demodicidosis (Demodex species)
Other sexually transmitted: Chancre (Haemophilus ducreyi); donovanosis
(Calymmatobacterium granulomatis); lymphogranuloma venereum
Whipple’s disease (Tropheryma whipplei)
Inflammatory/unknown Sarcoidosis
cause Crohn’s disease
Granulomatous vasculitis: Wegener’s, Churg-Strauss disease, bronchocentric
granulomatosis, polyarteritis nodosa
Primary biliary cirrhosis, hepatic granulomatosis
Giant cell arteritis
Granuloma annulare and actinic granuloma
Granulomatous rosacea, Granulomatous cheilitis
Necrobiosis lipoidica, Necrobiosis xanthogranuloma
Langerhans cell histiocytosis (histiocytosis X)
Granulomatous lesions of unknown significance (GLUS) syndromes
Identifiable inflammatory
aetiology
Hypersensitivity pneumonitis- (e.g. farmer’s lung, bird fancier’s lung, hot tub lung,
metal workers lung). Foreign body granulomas: beryllium, aluminium, titanium,
zirconium, talc, paraffin, pine tree pollen, clay, interferon-α injections, tattoos
Neoplastic Granulomatous mycosis fungoides
Lymphomas with histiocytic infiltration (Lennert’s disease)
Other causes Blau’s syndrome, chalazion, chronic granulomatous disease of childhood
Table 3. Some causes of granulomatous inflammation, table modified from references [79, 80].
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IFN-γ production in response to PPD stimulation of BAL lymphocytes has been shown to
distinguish M. tuberculosis infection from sarcoidosis in a patient with sarcoid-associated optic
neuropathy [77]. The QuantiFERON TB Gold has also been investigated in a cohort of 90
Japanese patients with sarcoidosis and was found to be positive in 3 patients (3.3%), which is
similar to the false-positive rate in healthy non-sarcoidosis subjects. In these 3 patients, their
specimens were negative for M. tuberculosis by acid fast staining, culture and PCR evaluation
of tissues and none developed tuberculosis infection at 1-year follow-up [81]. A recent study
compared the release of IFN-γ by BAL mononuclear cells and PBMC following ex vivo
stimulation with whole PPD, ESAT-6 and CFP-10 from German patients with sarcoidosis,
tuberculosis and healthy controls. They similarly found that BAL and PBMC IFN-γ release
was comparable amongst patients with sarcoidosis and controls, but less compared to patients
with tuberculosis [82]. Hence IGRAs such as the QuantiFERON TB Gold are specific for
tuberculosis infection and results are negative in patients with sarcoidosis.
Recent investigations have indicated that certain undegradable M. tuberculosis antigens (which
are not present in tuberculosis-specific IGRAs) may be potential pathogenic antigens in
sarcoidosis. Investigations utilising IFN-γ ELISPOT and flow cytometry indicated greater
PBMC and BAL TH1 responses to recombinant M. tuberculosis catalase-peroxidase (mKatG)
[83] and mKatG peptides in patients with sarcoidosis compared to healthy controls, but no
difference with PPD-positive (PPD+) control subjects, which profiles a possible pathogenic
antigen in sarcoidosis [67, 84-88]. A greater frequency of peripheral blood TH1 responses have
also been shown in patients with sarcoidosis compared with healthy PPD- controls following
stimulation with mycobacterial heat shock proteins [86, 89, 90] and M. tuberculosis peptides
from ESAT-6 [67, 84-88], mycolyl-transferase Antigen 85A [86, 91] and superoxide dismutase
A [86, 92]. Cellular immune responses against mycobacterial antigens were detected in cells
from patients with sarcoidosis that did not react to Trypanosoma brucei lysates [88] or the
neoantigen keyhole limpet hemocyanin [84], as well as Cytomegalovirus cell lysate and
Cytomegalovirus, Epstein-Barr virus and Influenza (CEF) peptides [67]. Recent findings with
flow cytometry have also shown significantly greater BAL CD4+ and CD8+ IFN-γ+ immune
responses to M. tuberculosis ESAT-6 and Propionibacterium acnes proteins in sarcoidosis patients
compared with healthy controls. This study also utilised matrix-assisted laser desorption
ionisation mass spectrometry (MALDI-IMS) to localise ESAT-6 and P. acnes signals within
sarcoidosis and control specimens. The authors identified localised signals consistent with
ESAT-6 in sarcoid granulomas, although there was no specific localisation of P. acnes in sarcoid
tissues [93]. This demonstrates specific mycobacterial antigen specificity inducing the immune
response in some patients with sarcoidosis.
5.2. Histopathological testing and Polymerase-Chain Reaction (PCR)
In sarcoidosis tissue micro-organisms are not detected through conventional staining techni‐
ques or cultures of non-caseating granulomas. Important differential diagnoses, including
infectious diseases must be excluded with histopathological testing using special stains for
acid-fast bacilli, fungi and microbial cultures. This is especially important if the patient has a
fever or when granulomas exhibit focal necrosis. Granulomas can also be found in regional
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lymph nodes of carcinomas or in primary tumours such as breast carcinoma and seminoma.
However, with immunohistochemical techniques, granulomas associated with neoplastic
processes are generally B-cell positive, whilst in sarcoidosis they are B-cell negative [94].
With the use of special stains or culture methods some investigators have also been able to
identify micro-organisms in sarcoid tissues, most commonly those resembling mycobacteria
[95]. Bacilli-like structures have also been observed using immunofluorescence techniques
[96]. Schaumann bodies, are a type of inclusion body found in sarcoidal giant cells, which
consist of small calcifications of calcium carbonate, iron and oxidised lipid with a lamellar
morphology. They are identified in up to 88% of cases of sarcoidosis and arise from lysosomes
[97]. They have interestingly been identified as sites of mycobacterial degradation by demon‐
strating the localisation of lysosomal components and mycobacterial antigens in immunohis‐
tologically stained sarcoidosis tissues [98]. Other investigators identified bacterial structures
in skin and lymph node biopsies [99], as well as blood, bronchial washings, ocular anterior
chamber fluid and cerebrospinal fluid from patients with sarcoidosis [100-104]. These organ‐
isms were identified as ‘L-form’ cell-wall deficient bacteria, which can occur during the life-
cycle of mycobacteria or in response to inhospitable conditions [95, 103, 105]. However, in a
larger multicentre study with 197 sarcoidosis cases and 150 controls an equal frequency of cell-
wall deficient forms were observed in blood specimens [101]. Sarcoidosis can also be histo‐
logically similar to lesions in atypical mycobacterial infections, including Mycobacterium avium-
intracellulare complex (MAC), Mycobacterium marinum and following BCG vaccination [95,
104]. Sarcoidosis is also an important differential diagnosis of M. marinum infection, where the
acid-fast bacilli are detected in 22% of active cases and use of polymerase chain reaction (PCR)
is more useful for diagnosis [106, 107].
In an attempt to improve the diagnostic sensitivity of traditional culture techniques, many
investigators have used DNA amplification techniques to search for mycobacterial or propio‐
nibacterial infection in sarcoidosis. Investigations have used PCR and nested PCR techniques
to identify mycobacterial and propionibacterial DNA or RNA in sarcoid tissue specimens,
including fresh tissues, paraffin-embedded tissues, granulomas, lymph nodes, lung and BAL
sediments and archival biopsy specimens. Several reports emerged indicating the presence of
mycobacterial DNA in some sarcoid tissues using DNA primers for M. tuberculosis complex
organisms [108-113], which could also suggest cell wall deficient mycobacterial infection. The
results have been inconsistent, however, as other groups did not find fluorescent in situ
hybridisation or PCR evidence of mycobacterial DNA or RNA in sarcoid tissues [114-116]. A
recent meta-analysis of 31 such studies identified that 231 out of 874 (26.4%) sarcoidosis biopsy
specimens had evidence of mycobacterial DNA, which is 9- to 19-fold higher than control tissue
samples, supporting an association between mycobacterial infection and sarcoidosis [117].
However, it is important to note that these results are not reproducible in all sarcoidosis
patients and that treatment of sarcoidosis with corticosteroids does not show reactivation of
tuberculosis- indicating the lack of a direct role of mycobacterial infection in sarcoidosis [118].
In a patient with negative microscopy, culture and PCR for tuberculosis; in the presence of
compatible clinical features and histology, a diagnosis of sarcoidosis can be made with
confidence.
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Propionibacterium acnes has also been isolated from sarcoid lesions [119] which has suggested
a role for this commensal organism in sarcoidosis. Using PCR to amplify segments of the 16S
rRNA of P. acnes or P. granulosum, several authors reported isolation of propionibacterial DNA
from sarcoid tissues [120-123], with a DNA signal intensity greater than surrounding non-
granulomatous tissue. These initial studies were followed by a cooperative study from
Japanese and European investigators that confirmed the presence of P. acnes and P. granulo‐
sum DNA in all but two of 108 sarcoidosis specimens obtained from both Japanese and
European biopsies [113]. However, P. acnes DNA was also reported in 57% of control tissues
including from healthy controls, suggesting that it is a common commensal organism in
peripheral lung tissues and mediastinal lymph nodes [124].
5.3. Exclusion of other infectious agents
A history of previous possible environmental exposure, or travel to endemic areas is important
to exclude infectious granulomatous diseases. Apart from culture and microscopy of speci‐
mens with special stains for fungi and acid-fast bacilli, other investigations can be performed
to exclude infection. These depend on the clinical context and may include serologic analyses.
Some specialised investigations may be used including identification of the histoplasmosis
urinary antigen and skin tests for fungi and protozoa (e.g. the Leishmanin test) [125]. In patients
with leprosy the ex vivo lymphocyte proliferation test in response to M. leprae as well as the
Mitsuda type of lepromin skin test [126] have been shown useful to differentiate leprosy from
cutaneous sarcoidosis [127]. Tissue must also be analysed for presence of metals, and foreign
bodies need to be excluded on microscopy.
5.4. Beryllium lymphocyte proliferation testing
The granulomas formed as a result of chronic beryllium exposure closely resembles that of
sarcoidosis, such that some investigators have suggested berylliosis defines a sarcoidosis
subset [128]. It is possible that in genetically susceptible individuals, distinct antigens can
precipitate sarcoidosis or sarcoidosis-like diseases [129]. A history of occupational or environ‐
mental exposure to beryllium is important when considering a diagnosis of sarcoidosis, in
patients who have been exposed to the metal dust or fumes. The beryllium lymphocyte
proliferation test has been used in the diagnosis of chronic beryllium disease to distinguish it
from sarcoidosis and other granulomatous diseases [128]. This laboratory investigation
involves the addition of beryllium salts to a sample of peripheral blood or BAL fluid, which
can lead to mononuclear cell proliferation, only in patients with berylliosis [66]. Beryllium
sulphate stimulation of BAL from patients with chronic beryllium disease induced greater TH1
immune responses, with markedly elevated numbers of CD4+ INF-γ and IL-2 secreting
beryllium-specific lymphocytes, as well as ex vivo lymphocyte proliferation compared to
healthy controls [130, 131], making it a useful investigation to distinguish berylliosis from
sarcoidosis. Patients with chronic beryllium disease can also have preserved skin test-
reactivity to common recall antigens such as candida, tetanus and mycobacteria, as well as
hyperresponsive DTH to beryllium with the beryllium patch test, unlike sarcoidosis, where
patients demonstrate cutaneous anergy [132]. Interestingly, patients with severe chronic
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beryllium disease may have lymphopenia, calcium metabolism abnormalities, elevation of
serum ACE and elevated CD4+ T-cells at sites of inflammation- similar to sarcoidosis, but have
negative Kveim test reactions [132].
6. The Kveim-Siltzbach test
Before the use of fibre-optic bronchoscopy and BAL, the Kveim-Siltzbach test was used as the
diagnostic test for sarcoidosis, although now it remains of historical importance only. It was
performed by intradermal injection of Kveim-reagent, a validated suspension of allogeneic
human sarcoid tissue, typically sarcoid spleen or lymph nodes homogenised in phosphate-
buffered saline, pasteurised, resuspended with 0.25% phenol, while later preparations were
irradiated [133, 134]. The resultant papule at the injection site was biopsied three to six weeks
later and presence of non-caseating granulomas indicated sarcoidosis [135, 136]. Kveim
reactions can also be induced from similar preparations made from sarcoidosis BAL cells or
peripheral blood monocytes, suggesting systemic dissemination of the inciting agent by
mononuclear phagocytes [38, 137, 138]. Ansgar Kveim was the first to report in the 1940s that
biopsy of these papules demonstrated the presence of epithelioid granulomas that were
histologically identical to granulomas observed in sarcoid tissues [135]. In 1967 Siltzbach
demonstrated that >80% of sarcoid patients worldwide reacted positively to a single batch of
Kveim reagent, with <1% false positive rate of non-specific reactions in control subjects,
indicating the possibility of a common antigen in the aetiology of sarcoidosis [139]. The test
was very useful in distinguishing sarcoidosis from other granulomatous diseases [140]. A
medical centre that performed >10,000 Kveim-Siltzbach tests over fifty years identified a true
positive rate of >50% and false negative rate of nearly zero [10]. This test is now rarely used as
no commercially available preparation of the reagent exists, with the additional problem that
each new Kveim-Siltzbach preparation requires validation in vivo [136]. Furthermore, use of
human tissue extracts for clinical purposes presents constraints, including risks of transmitting
infections such as Creutzfeldt-Jakob disease even after heating, phenol and irradiation [141].
Because of the four week delay in response and need for biopsies, attempts were made to
develop a rapid in-vitro Kveim-Siltzbach test [142, 143]. These have been based on examin‐
ing morphology of lymphoblastic transformation or macrophage activation in response to
Kveim  reagent,  which  was  identified  but  most  results  were  controversial  and  negative
[144-146]. A study investigating stimulation of BAL and blood lymphocytes from sarcoido‐
sis  patients  using  Kveim  antigen  did  not  show  any  significant  increase  in  lymphocyte
responses to Kveim antigen as measured by lymphocyte DNA synthesis [147]. Hence no
comprehensive  in  vitro  Kveim-Siltzbach test  has  been developed that  could be  used for
diagnostic  purposes.  Nevertheless,  Kveim reagent  or  sarcoid tissues can theoretically  be
utilised as a lymphocyte stimulus ex vivo. Improvements to in vitro Kveim tests could include
purer validated preparations [148], addition of macrophages for enhanced antigen presen‐
tation and reactivity, avoidance of sarcoid sera known to inhibit lymphocyte function and
advanced immunological techniques [149].
Laboratory Investigations and Immunological Testing in Sarcoidosis
http://dx.doi.org/10.5772/55294
213
It was later identified that the granulomagenic factor was an insoluble undegradable partic‐
ulate, devoid of a consistently identifiable infectious agent by electron microscopy that
aggregated in phagolysosomes of antigen presenting cells [38]. The Kveim reaction is charac‐
terised by an influx of mainly CD4+ T cells which express a restricted variable-β (Vβ) region
of the T-cell receptor (TCR), indicating oligoclonal expansion in response to a limited number
of antigens [150]. This may also indicate that the aetiological agent may be present in Kveim
reagent as Vα and Vβ specific TCR oligoclonality has also been identified in T-cells from sites
of sarcoid inflammation [150, 151]. Based on hypotheses that pathogenic antigens in sarcoi‐
dosis have similar physicochemical properties as Kveim reagent (including poor solubility in
neutral detergent and resistance to acidity and protease digestion) [152], this led to a limited
proteomics approach to determine potential antigens with these characteristics in sarcoidosis
tissue homogenates [153]. Using matrix-assisted laser desorption/ionisation time of flight
(MALDI-TOF) mass spectroscopy and protein immunoblotting, mycobacterial catalase-
peroxidase (KatG) protein was identified in 55% of samples that was also a target of circulating
IgG in 48% of sarcoidosis subjects [153]. This suggested that this remnant mycobacterial protein
is one target of the adaptive immune response driving granulomatous inflammation in at least
a subset of sarcoidosis tissues. Subsequently, investigations with IFN-γ ELISPOT and flow
cytometry following intracellular staining for IFN-γ indicated greater peripheral blood
mononuclear cell (PBMC) and BAL TH1 responses to recombinant Mycobacterium tuberculosis
KatG [83] and KatG peptides in patients with sarcoidosis compared to healthy controls.
However, there was no difference when compared with PBMC from PPD+ control subjects,
which profiles a pathogenic antigen in some patients with sarcoidosis [84,86-88]. We also
determined that stimulation with pooled peptides from M. tuberculosis Early-Secretory
Antigen Target-6 (ESAT-6) and KatG induced greater numbers of IFN-γ producing T-cells and
elevated IL-2, IL-6 and TNF-α in sarcoidosis compared to PPD- healthy control subjects [67].
Since these mycobacterial antigens do not induce immune responses in all patients with
sarcoidosis, newer, more specific approaches are thus needed to identify other potential
antigens in Kveim reagent.
7. Important markers of granulomatous inflammation
7.1. Angiotensin Converting Enzyme (ACE)
Most clinicians are familiar with ACE, as it is the glycoprotein enzyme responsible for
converting angiotensin I to angiotensin II, for which ACE inhibitors are used to treat hyper‐
tension and congestive heart failure. ACE is typically measured using a functional assay which
measures ACE activity rather than ACE concentrations [154]. As the test is a functional
biological assay, the presence of ACE inhibitors in the patient’s serum can affect measurements
[155]. ACE activity levels also tend to be higher in younger subjects [156].
ACE is a ubiquitous enzyme secreted by monocytes and macrophages, as well as pulmona‐
ry endothelial cells into the bloodstream where it exerts its actions. Serum ACE was first
reported by Lieberman in 1975 as being elevated in patients with untreated active sarcoido‐
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sis [157, 158]. Sarcoid granulomas produce ACE, with the source being epithelioid and giant
cells from the macrophage line [159]. Serum ACE activity is elevated in ~60% of patients
with sarcoidosis [10, 160, 161], although values can vary depending on the time of diagnosis,
extent  of  disease,  acute  or  chronic  disease  and  radiological  stage  and  corticosteroid
treatment. It is a useful diagnostic and prognostic tool, but normal levels do not exclude
sarcoidosis and false positives are not uncommon. Serum ACE may also be elevated in a
variety  of  other  granulomatous  and  non-granulomatous  diseases  such  as  pulmonary
silicosis,  asbestosis  [162],  chronic  beryllium  disease  [163],  histoplasmosis  [164],  miliary
tuberculosis, leprosy [165, 166], diabetes mellitus [167], hyperthyroidism [168] and Gauch‐
er’s  disease  [169].  Hence  serum  ACE  activity  in  sarcoidosis  is  a  marker  of  granuloma
formation but  with  limited sensitivity  and specificity.  It  must  be  interpreted with other
markers of sarcoidosis, along with clinical and radiological features, although serial values
may  be  helpful  in  disease  monitoring.  One  confounding  factor  is  that  ACE  activity  in
biological fluids is also affected by insertion/deletion (I/D) polymorphisms of the ACE gene
and the Angiotensin II receptor 1 (AT2R1) gene [170]. Patients can be classified into three
groups based on the ACE gene polymorphisms,  including II,  ID and DD. Homozygous
carriers of the deletion mutation (DD) or the insertion (II) are associated with the highest
and lowest ACE levels respectively, which can lead to underestimation or overestimation
[171].  Patient genotyping for ACE I/D polymorphisms may improve assessment of  ACE
activity, however, there is a need for genotype-corrected reference levels.
ACE activity is also measurable and elevated in BAL fluid of patients with sarcoidosis [172]
and is considered to provide better prognostic information than serum ACE. ACE has also
been measured in urine and cerebrospinal fluid (CSF) and other biological fluids. Elevat‐
ed CSF ACE has been identified as a useful marker in patients with suspected neurosarcoi‐
dosis, with values ≥8nmol/mL/min having a specificity of 94% and sensitivity of 55% in one
study [173].
7.2. Lysozyme
Lysozyme is another monocyte-macrophage derived enzyme that may be considered a
potential marker of macrophage activity. It is normally found in the granules of monocytes,
macrophages, and neutrophils, where it may be released and is readily detectable in tears,
saliva, airway secretions and CSF. Elevated serum lysozyme has been found in patients with
active sarcoidosis, in ~30% of patients at clinical onset [30, 174, 175] and had been identified
before the ACE test became available [176]. In sarcoidosis and in the Kveim reaction, immu‐
nohistochemical studies have identified the source of lysozyme as macrophages and epithe‐
lioid giant cells involved in granuloma formation [177]. Several authors have compared serum
lysozyme with ACE and have identified a positive correlation between them, as both tests are
positive in the majority of patients with acute disease [178, 179]. Lysozyme may be used to aid
in the diagnosis of sarcoidosis and monitor disease course. However, the use of serum
lysozyme is limited in clinical practice by its low sensitivity and specificity compared to other
biomarkers, as it is also elevated in several other diseases [30].
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7.3. Neopterin
Neopterin is a metabolite of guanosine triphosphate released by activated macrophages in
response to IFN-γ [30, 180] and is elevated in serum and urine of patients with sarcoidosis
[181, 182]. Other groups have detected elevated neopterin in patients with active disease [40,
183, 184] and have noted that levels fall with disease resolution [185, 186]. Interestingly,
comparing neopterin to other serum and BAL markers demonstrated that elevated neopterin
and sIL-2R were present in patients who were more likely to have progressive disease
requiring long-term treatment with corticosteroids [40, 44].
7.4. Chitotriosidase
Chitotriosidase is a member of a group of enzymes involved in the breakdown of chitins
(polymers of N-acetylglucosamine- commonly found in cell walls of fungi and exoskeletal
elements of some animals and arthropods) [187]. The role of chitotriosidase in the pathogenesis
of sarcoidosis is not clearly understood. It is believed that chronic over-expression, along with
CCL18 over-expression (a chemokine involved in fibrotic remodelling of diffuse lung diseases)
may induce pro-fibrotic TH2 cytokines and fibronectin, predisposing to development of fibrosis
[188]. In situ hybridisation has confirmed that alveolar macrophages from BAL fluid of patients
with sarcoidosis are the primary source of this mediator [188, 189]. Serum chitotriosidase has
been identified to be elevated in the serum of >90% of patients with sarcoidosis [190]. Signifi‐
cantly greater chitotriosidase activity was also demonstrated in the BAL and serum of
sarcoidosis patients than in controls and levels generally increase with disease progression.
BAL chitotriosidase activity also correlated with sarcoidosis radiological stages, serum ACE
activity and radiological CT findings of fibrotic lung involvement [191]. Levels also decrease
significantly with therapeutic interventions indicating that it may be a suitable marker of
disease severity and granulomatous inflammation in sarcoidosis [187] and that it may have
potential for identifying patients at risk of developing chronic fibrotic disease [191].
7.5. Other markers
Serum amyloid A is an amyloid precursor protein related to the high-density lipoprotein and
is an innate receptor ligand with some physicochemical properties seen in the Kveim reagent
[152]. It has been found to regulate granulomatous inflammation through Toll-like receptor-2
in experimental models of mKatG induced granulomatous lung inflammation and using
alveolar macrophages from sarcoid patients [192]. Serum amyloid A is also an acute phase
protein that is released together with C-reactive protein by the liver under systemic IL-1 and
IL-6 stimulation and is hence also regarded as a nonspecific inflammatory marker of sarcoi‐
dosis, although it is less sensitive and specific than other markers such as sIL-2R [23].
Adenosine deaminase is an enzyme for purine metabolism that is important for differentiation
of T lymphocytes. It has been studied in sarcoidosis and tuberculosis and is elevated in BAL
fluid and serum in some cases of sarcoidosis [193]. Some studies have found serum adenosine
deaminase to be useful, finding elevated levels in active sarcoidosis compared to inactive
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disease and healthy controls [194], whilst others found conflicting results indicating no
relationship with disease activity [179].
Endothelin-1 is a vasoactive bronchoconstrictive peptide identified in pulmonary fibroproli‐
ferative processes and has been assessed in the serum, BAL, urine and lung tissues in sarcoi‐
dosis [195-197]. Elevated endothelin-1 levels have been associated with the clinical course of
sarcoidosis and the degree of lymphocytic alveolitis and number of BAL macrophages [196,
197]. It is hypothesised that endothelin-1 may be involved in the development of pulmonary
hypertension and fibrosis, although further studies are needed to confirm this in sarcoidosis.
Other markers studied in sarcoidosis include neutrophils and neutrophil-associated markers,
which have been noted to be associated with chronic disease in sarcoidosis with progressive
fibrosis and diffuse fibrotic lung disease. Important neutrophil markers studied in sarcoidosis
include elastase and collagenase. Elastase appears to have a limited role in monitoring
sarcoidosis although is elevated in those with chronic Stage III radiological disease [198].
Collagenase is elevated in the serum of some patients with sarcoidosis and elevated BAL
collagenase has also been measured in conjunction with elevated fibronectin and is associated
with more progressive and fibrotic disease [199].
8. A proteomics approach
Proteomics is emerging as a useful method of simultaneously analysing large numbers of
proteins, including protein structure and functions in biological samples, as well as identifying
profiles characteristic of disease processes. This approach has the potential to make new
discoveries as the findings are usually independent of any earlier specific protein biomarkers.
In sarcoidosis various proteomic techniques have been used for profiling protein patterns in
BAL fluid and serum. Two-dimensional electrophoresis and mass spectrometry identified a
total of 85 proteins in BAL fluid, of which 38 were newly identified in BAL from patients with
sarcoidosis and idiopathic pulmonary fibrosis [200]. Proteins identified included locally
secreted, plasma derived, proteolytic or cell damage products that have pro-inflammatory,
anti-inflammatory and anti-protease activity. Compared with systemic sclerosis and idiopath‐
ic pulmonary fibrosis, BAL from patients with sarcoidosis also had greater acute phase proteins
including ceruloplasmin, haptoglobin β, β2-microglobulin and α1-antichymotrypsin [59].
Other techniques have included applying narrow range pH gradients, which also identified
new groups of proteins in the BAL and serum of patients with sarcoidosis, many of which are
proteins involved in inflammatory and oxidative stress processes [201, 202]. This same group
also applied difference gel electrophoresis proteomics to the analysis of BAL from patients at
risk of developing chronic sarcoidosis (with a HLA-DRB1*15 genotype) compared with
patients with chronic beryllium disease and controls. The investigators identified differing
protein patterns between the three groups including increased peroxiredoxin 5, heat shock
protein 70, complement C3, annexin A2 and transthyretin in sarcoidosis patients compared to
the control group [203]. Other novel approaches have utilised surface-enhanced laser desorp‐
tion ionization-time of flight-mass spectrometry (SELDI-TOF-MS) and have found different
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disease-related proteins and protein patterns in serum; identifying the α2 chain of haptoglobin
as a potential serologic marker [204]. This was also performed in BAL fluid of patients with
sarcoidosis identifying proteins that may related to clinical course, including α1-antitrypsin,
protocadherin-2 precursor and albumin [205]. Proteomic analysis has provided a large-scale
of novel data identifying protein biomarkers in sarcoidosis, which are different to those of
healthy controls and patients with other interstitial lung diseases. However, much still needs
to be done in identifying their role in the pathogenesis and validating the clinical utility of
these markers in patients with sarcoidosis through further large-scale studies.
9. Exhaled breath analysis
Approximately 90% of patients with sarcoidosis have pulmonary disease involvement. It has
hence been proposed that exhaled biomarkers from the lungs of patients with sarcoidosis could
potentially be used to provide novel insights into the immunopathogenesis of the disease as
well as for diagnosis and disease monitoring [1]. Initial studies investigating exhaled breath
in sarcoidosis identified increased exhaled nitric oxide (FENO) in patients with sarcoidosis
compared to healthy controls, which then reduced significantly after 6 weeks of treatment with
corticosteroids [206]. Increased exhaled nitric oxide possibly reflects disease activity, and is
associated with increased TH1 immune responses. This may arise through up-regulation of
nitric oxide synthase, which is induced (iNOS) by increased IFN-γ and TNF-α in active disease
[206]. Other investigators however, found conflicting results, identifying that FENO from 59
patients with sarcoidosis did not differ significantly from 44 healthy controls and were not
related to the extent of individual CT scan abnormalities or pulmonary function impairment
[207]. Similar results have been obtained in a recent study examining multiple flow rates
measurement of exhaled nitric oxide in patients with sarcoidosis and healthy controls, as well
as patients treated with corticosteroids [208], which indicated that exhaled nitric oxide
measurement did not appear to be a clinically useful method of monitoring disease progression
in sarcoidosis. One study recently investigated the use of exhaled carbon monoxide (CO) in
sarcoidosis, an oxidative stress biomarker for alveolar macrophage heme oxygenase activity.
The authors identified a significantly elevated exhaled CO in patients with sarcoidosis
compared to healthy controls and patients with miscellaneous interstitial lung disease [209].
However, the prognostic value of this measurement remains undefined and may be affected
by cigarette smoke.
Exhaled breath condensate (EBC) analysis is a simple method of sampling airway lining fluids
that has been shown to be useful for analysing exhaled breath markers [210-212] and is less
invasive compared with induced sputum and BAL. Total protein levels are much higher in
BAL than EBC [213], but nevertheless, the presence of a few biomarkers has been demonstrated
in the EBC of patients with sarcoidosis. Levels of inflammatory markers e.g. TNF-α, Insulin-
like growth factor-1 (IGF-1), and plasminogen activator inhibitor-1 (PAI-1) have been shown
to be comparable and closely correlated in EBC and BAL samples, however, EBC IL-6 con‐
centration was significantly lower when compared with that in BAL fluid in patients with
sarcoidosis [214]. This study concluded that besides IL-6, EBC reflects cytokine production in
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the lung as effectively as BAL and may allow for a simplified sampling method. Hepatocyte
growth factor (HGF) is produced by fibroblasts, causing strong epithelial proliferative
responses and has been found to be elevated in EBC of patients with pneumonia [215].
However, levels of HGF are comparable in both EBC and BAL fluid of patients with sarcoidosis
and healthy controls, suggesting it is not useful as an EBC biomarker in sarcoidosis [216].
Transforming growth factor-β1 (TGF-β1) has also recently been identified in the EBC of patients
with sarcoidosis, along with vascular endothelial growth factor (VEGF), PAI-1, TNF-α and
IL-8 but not urokinase-type plasminogen activator (uPA) [217]. TGF-β is implicated in fibrosis
by inducing extracellular matrix synthesis and has been detected in ex vivo BAL cell cultures
from patients with sarcoidosis [30], suggesting it may be a useful sarcoid EBC marker. Markers
of granulomatous inflammation identified in our laboratory at greater levels in the EBC of
patients with sarcoidosis compared to healthy controls include neopterin and TGF-β1 (H.
Ahmadzai, D. Wakefield, P.S. Thomas; unpublished observations), which could potentially be
measured as airway markers of sarcoid activity.
Recent investigations have identified exhaled eicosanoids including 8-isoprostane and
cysteinyl leukotrienes as being elevated in the EBC and BAL fluid of sarcoidosis patients [218].
A correlation has been identified between the levels of 8-isoprostane and leukotriene B4 in BAL
fluid and EBC of patients with sarcoidosis [219]. EBC levels of 8-isoprostane also positively
correlate with the percentage of eosinophils in BAL and negatively with neutrophils [220,
221]. 8-isoprostane levels are increased in active sarcoidosis compared to healthy subjects,
which may serve as a marker of disease severity and indicate increased oxidation [220].
Increased markers of oxidative stress including elevated hydrogen peroxide levels have also
been demonstrated in EBC and BAL of sarcoidosis patients, as well as end-products of lipid
peroxidation [222]. Growth factors, reactive oxygen species and products of oxidative stress
in BAL and exhaled breath cannot yet be considered specific prognostic markers in sarcoidosis.
Further research is needed into their potential clinical applications for disease monitoring.
10. Novel and experimental testing and conclusions
Laboratory and immunological testing has provided significant advances in the understanding
of sarcoid immunopathogenesis and has allowed for easier diagnosis. Important recent
findings have included the investigation of the immunology of the disease, through the
TH1/TH2/TH17 paradigm, which could provide further new insights into immunopathogenesis
and potential treatments. Novel methods of identifying peripheral blood T-cell activation, such
as with an in vitro Kveim reaction, could identify causative antigenic peptides. Large-scale
studies validating initial proteomics findings from BAL and serum need to be conducted to
identify the different clinical phenotypes of sarcoidosis and recognise patients at risk of chronic
disease and pulmonary fibrosis. Simple, less invasive investigations such as exhaled breath
analysis also need to be improved for clinical use. There is also potential for advanced
immunological investigations including multiplex protein and gene expression technology to
further investigate this intriguing disease. Although various biomarkers have been identified
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and proposed for diagnosis and monitoring, there is still no sufficiently specific or sensitive
disease marker for clinical practice and much is yet to be understood.
Author details
Hasib Ahmadzai1,2*, Paul S. Thomas1,2,3 and Denis Wakefield1,3,4
*Address all correspondence to: h.ahmadzai@unswalumni.com
1 Inflammation and Infection Research Centre (IIRC), Faculty of Medicine, University of
New South Wales, Sydney, NSW, Australia
2 Department of Respiratory Medicine, Prince of Wales Hospital, Randwick, NSW, Australia
3 Multidisciplinary Sarcoidosis Clinic, Prince of Wales Hospital, Randwick, NSW, Australia
4 Immunology of the Eye Clinic, St. Vincent’s Clinic, Darlinghurst, NSW, Australia
References
[1] Ahmadzai H, Wakefield D, Thomas PS. The potential of the immunological markers
of sarcoidosis in exhaled breath and peripheral blood as future diagnostic and moni‐
toring techniques. Inflammopharmacology. 2011;19(2):55-68.
[2] Statement on Sarcoidosis. Joint Statement of the American Thoracic Society (ATS),
the European Respiratory Society (ERS) and the World Association of Sarcoidosis
and other Granulomatous Disorders (WASOG), adapted by the ATS Board of Direc‐
tors and by the ERS Executive Committee. American Journal of Respiratory and Crit‐
ical Care Medicine. 1999;160(2):736-55.
[3] Gerke AK, Hunninghake G. The Immunology of Sarcoidosis. Clinics in Chest Medi‐
cine. 2008;29(3):379-90.
[4] Hunninghake GW, Fulmer JD, Young RC Jr, Gadek JE, Crystal RG. Localization of
the immune response in sarcoidosis. The American Review of Respiratory Disease.
1979;120(1):49-57.
[5] Mathew S, Bauer KL, Fischoeder A, Bhardwaj N, Oliver SJ. The Anergic State in Sar‐
coidosis is Associated with Diminished Dendritic Cell Function. The Journal of Im‐
munology. 2008;181:746-55.
[6] Grunewald J, Eklund A. Role of CD4+ T cells in Sarcoidosis. Proceedings of the
American Thoracic Society. 2007;4(5):461-4.
Sarcoidosis220
[7] Mert A, Bilir M, Ozaras R, Tabak F, Karayel T, Senturk H. Results of Hepatitis B Vac‐
cination in Sarcoidosis. Respiration. 2000;67(5):543-5.
[8] Nunes H, Soler P, Valeyre D. Pulmonary sarcoidosis. Allergy. 2005;60(5):565-82.
[9] Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H Jr, Bresnitz EA, et
al. Clinical characteristics of patients in a case control study of sarcoidosis. American
Journal of Respiratory and Critical Care Medicine. 2001;164(10 Pt 1):1885-9.
[10] Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. The New England Journal of
Medicine. 2007;357(21):2153-65.
[11] Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, et al.
ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European
Respiratory Society/World Association of Sarcoidosis and other Granulomatous Dis‐
orders. Sarcoidosis, Vasculitis & Diffuse Lung Diseases. 1999;16(2):149-73.
[12] Berliner AR, Haas M, Choi MJ. Sarcoidosis: the nephrologist's perspective. American
Journal of Kidney Diseases. 2006;48(5):856-70.
[13] Ponce C, Gujral JS. Renal failure and hypercalcemia as initial manifestations of ex‐
trapulmonary sarcoidosis. Southern Medical Journal. 2004;97(6):590-2.
[14] Rizzato G, Colombo P. Nephrolithiasis as a presenting feature of chronic sarcoidosis:
a prospective study. Sarcoidosis, Vasculitis & Diffuse Lung Diseases. 1996;13(2):
167-72.
[15] Reichel H, Koeffler HP, Barbers R, Norman AW. Regulation of 1,25-dihydroxyvita‐
min D3 production by cultured alveolar macrophages from normal human donors
and from patients with pulmonary sarcoidosis. Journal of Clinical Endocrinology
and Metabolism. 1987;65(6):1201-9.
[16] Clavel S, Garabedian M, Tau C, Orgiazzi J. Extrarenal synthesis of calcitriol in sarcoi‐
dosis. [Article in French]. Presse médicale. 1987;16(3):107-10.
[17] Inui N, Murayama A, Sasaki S, Suda T, Chida K, Kato S, et al. Correlation between
25-hydroxyvitamin D3 1 alpha-hydroxylase gene expression in alveolar macrophag‐
es and the activity of sarcoidosis. The American Journal of Medicine. 2001;110(9):
687-93.
[18] Barbour GL, Coburn JW, Slatopolsky E, Norman AW, Horst RL. Hypercalcemia in an
anephric patient with sarcoidosis: evidence for extrarenal generation of 1,25-dihy‐
droxyvitamin D. The New England Journal of Medicine. 1981;305(8):440-3.
[19] Richmond BW, Drake WP. Vitamin D, innate immunity, and sarcoidosis granuloma‐
tous inflammation: insights from mycobacterial research. Current Opinion in Pulmo‐
nary Medicine. 2010;16(5):461-4.
Laboratory Investigations and Immunological Testing in Sarcoidosis
http://dx.doi.org/10.5772/55294
221
[20] Playford EG, Bansal AS, Looke DF, Whitby M, Hogan PG. Hypercalcaemia and ele‐
vated 1,25(OH)(2)D(3) levels associated with disseminated Mycobacterium avium in‐
fection in AIDS. The Journal of Infection. 2001;42(2):157-8.
[21] Liu JW, Huang TC, Lu YC, Liu HT, Li CC, Wu JJ, et al. Acute disseminated histoplas‐
mosis complicated with hypercalcaemia. The Journal of Infection. 1999;39(1):88-90.
[22] Caldwell JW, Arsura EL, Kilgore WB, Reddy CM, Johnson RH. Hypercalcemia in pa‐
tients with disseminated coccidioidomycosis. The American Journal of the Medical
Sciences. 2004;327(1):15-8.
[23] Rothkrantz-Kos S, van Dieijen-Visser MP, Mulder PG, Drent M. Potential usefulness
of inflammatory markers to monitor respiratory functional impairment in sarcoido‐
sis. Clinical Chemistry. 2003;49(9):1510-7.
[24] Shorr AF, Murphy FT, Gilliland WR, Hnatiuk W. Osseous disease in patients with
pulmonary sarcoidosis and musculoskeletal symptoms. Respiratory Medicine.
2000;94(3):228-32.
[25] Greenberg G, James DG, Feizi T, Bird R. Serum-proteins in sarcoidosis. The Lancet.
1964;2(7373):1315-5.
[26] Drent M, Wirnsberger RM, de Vries J, van Dieijen-Visser MP, Wouters EF, Schols
AM. Association of fatigue with an acute phase response in sarcoidosis. European
Respiratory Journal. 1999;13(4):718-22.
[27] Hind CR, Flint KC, Hudspith BN, Felmingham D, Brostoff J, Johnson NM. Serum C-
reactive protein concentrations in patients with pulmonary sarcoidosis. Thorax.
1987;42(5):332-5.
[28] Peros-Golubicić T. Serum C-reactive protein measurement in the detection of inter‐
current infection in patients with sarcoidosis. Acta Medica Croatica. 1995;49(1):1-3.
[29] Miyara M, Amoura Z, Parizot C, Badoual C, Dorgham K, Trad S, et al. The immune
paradox of sarcoidosis and regulatory T cells. The Journal of Experimental Medicine.
2006;203(2):359-70.
[30] Bargagli E, Mazzi A, Rottoli P. Markers of Inflammation in sarcoidosis: Blood, Urine,
BAL, Sputum, and Exhaled Gas. Clinics in Chest Medicine. 2008;29(3):445- 58.
[31] Ziegenhagen MW, Muller-Quernheim J. The cytokine network in sarcoidosis and its
clinical relevance. Journal of Internal Medicine. 2003;253:18-30.
[32] Betelli E, Kom T, Oukka M, Kuchroo VK. Induction and effector functions of TH17
cells. Nature. 2008;453(1051-1057).
[33] Facco M, Cabrelle A, Teramo A, Olivieri V, Gnoato M, Teolato S, et al. Sarcoidosis is
a Th1/Th17 multisystem disorder. Thorax. 2010;66(2):144-50.
Sarcoidosis222
[34] Ten Berge B, Paats MS, Bergen IM, van den Blink B, Hoogsteden HC, Lambrecht BN,
et al. Increased IL-17A expression in granulomas and in circulating memory T cells in
sarcoidosis. Rheumatology. 2012;51(1):37-46.
[35] Judson MA, Marchell RM, Mascelli M, Piantone A, Barnathan ES, Petty KJ, et al. Mo‐
lecular profiling and gene expression analysis in cutaneous sarcoidosis: the role of in‐
terleukin-12, interleukin-23, and the T-helper 17 pathway. Journal of the American
Academy of Dermatology. 2012;66(6):901-10.
[36] Meloni F, Solari N, Cavagna L, Morosini M, Montecucco CM, Fietta AM. Frequency
of Th1, Th2 and Th17 producing T lymphocytes in bronchoalveolar lavage of patients
with systemic sclerosis. Clinical and experimental Rheumatology. 2009;27(5):765-72.
[37] Wikén M, Idali F, Al Hayja MA, Grunewald J, Eklund A, Wahlström J. No evidence
of altered alveolar macrophage polarization, but reduced expression of TLR2 in
bronchoalveolar lavage cells in sarcoidosis. Respiratory Research. 2010;11(1):121-33.
[38] Kataria YP, Holter JF. Immunology of sarcoidosis. Clinics in Chest Medicine.
1997;18(4):719-39.
[39] Olejniczak K, Kasprzak A. Biological properties of interleukin 2 and its role in patho‐
genesis of selected diseases--a review. Medical Science Monitor.
2008;14(10):RA179-89.
[40] Ziegenhagen MW, Rothe ME, Schlaak M, Müller-Quernheim J. Bronchoalveolar and
serological parameters reflecting the severity of sarcoidosis. European Respiratory
Journal. 2003;21(3):407-13.
[41] Grutters JC, Fellrath JM, Mulder L, Janssen R, van den Bosch JM, van Velzen-Blad H.
Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: a
clinical evaluation. Chest. 2003;124(1):186-95.
[42] Lawrence EC, Brousseau KP, Berger MB, Kurman CC, Marcon L, Nelson DL. Elevat‐
ed concentrations of soluble interleukin-2 receptors in serum samples and bronchoal‐
veolar lavage fluids in active sarcoidosis. American Review of Respiratory Disease.
1988;137(4):759-64.
[43] Keicho N, Kitamura K, Takaku F, Yotsumoto H. Serum concentration of soluble in‐
terleukin-2 receptor as a sensitive parameter of disease activity in sarcoidosis. Chest.
1990;98(5):1125-9.
[44] Prasse A, Katic C, Germann M, Buchwald A, Zissel G, Müller-Quernheim J. Pheno‐
typing sarcoidosis from a pulmonary perspective. American Journal of Respiratory
and Critical Care Medicine. 2008;177(3):330-6.
[45] Parrish RW, Williams JD, Davies BH. Serum beta-2-microglobulin and angiotensin-
converting enzyme activity in sarcoidosis. Thorax. 1982;37(12):936-40.
Laboratory Investigations and Immunological Testing in Sarcoidosis
http://dx.doi.org/10.5772/55294
223
[46] Selroos O, Klockars M. Relation between clinical stage of sarcoidosis and serum val‐
ues of angiotensin converting enzyme and beta2-microglobulin. Sarcoidosis.
1987;4(1):13-7.
[47] Mornex JF, Revillard JP, Vincent C, Deteix P, Brune J. Elevated serum beta 2-micro‐
globulin levels and C1q-binding immune complexes in sarcoidosis. Biomedicine.
1979;31(7):210-3.
[48] Oksanen V. New cerebrospinal fluid, neurophysiological and neuroradiological ex‐
aminations in the diagnosis and follow-up of neurosarcoidosis. Sarcoidosis.
1987;4(2):105-10.
[49] Costabel U, Bonella F, Ohshimo S, Guzman J. Diagnostic modalities in sarcoidosis:
BAL, EBUS, and PET. Seminars in Respiratory and Critical Care Medicine. 2010;31(4):
404-8.
[50] Agostini C, Trentin L, Zambello R, Bulian P, Siviero F, Masciarelli M, et al. CD8 al‐
veolitis in sarcoidosis: incidence, phenotypic characteristics, and clinical features.
The American Journal of Medicine. 1993;95(5):466-72.
[51] Wahlström J, Berlin M, Sköld CM, Wigzell H, Eklund A, Grunewald J. Phenotypic
analysis of lymphocytes and monocytes/macrophages in peripheral blood and bron‐
choalveolar lavage fluid from patients with pulmonary sarcoidosis. Thorax.
1999;54:339-46.
[52] Hill TA, Lightman S, Pantelidis P, Abdallah A, Spagnolo P, du Bois RM. Intracellular
cytokine profiles and T cell activation in pulmonary sarcoidosis. Cytokine.
2008;42:289-92.
[53] Saltini C, Spurzem JR, Lee JJ, Pinkston P, Crystal RG. Spontaneous release of inter‐
leukin 2 by lung T lymphocytes in active pulmonary sarcoidosis is primarily from
the Leu3+DR+ T cell subset. Journal of Clinical Investigation. 1986;77(6):1962-70.
[54] Katchar K, Wahlström J, Eklund A, Grunewald J. Highly activated T-cell receptor
AV2S3(+) CD4(+) lung T-cell expansions in pulmonary sarcoidosis. American Journal
of Respiratory and Critical Care Medicine. 2001;163(7):1540-5.
[55] Wahlström J, Dengjel J, Persson B, Duyar H, Rammensee HG, Stevanović S, et al.
Identification of HLA-DR-bound peptides presented by human bronchoalveolar lav‐
age cells in sarcoidosis. Journal of Clinical Investigation. 2007;117(11):3576-82.
[56] Inui N, Chida K, Suda T, Nakamura H. TH1/TH2 and TC1/TC2 profiles in peripheral
blood and bronchoalveolar lavage fluid cells in pulmonary sarcoidosis. Journal of Al‐
lergy and Clinical Immunology. 2001;107(2):337-44.
[57] M llers M, Aries SP, Dr mann D, Mascher B, Braun J, Dalhoff K. Intracellular cytokine
repertoire in different T cell subsets from patients with sarcoidosis. Thorax.
2001;56:487-93.
Sarcoidosis224
[58] Wahlström J, Katchar K, Wigzell H, Olerup O, Eklund A, Grunewald J. Analysis of
Intracellular Cytokines in CD4+ and CD8+ Lung and Blood T cells in Sarcoidosis.
American Journal of Respiratory and Critical Care Medicine. 2001;163:115-21.
[59] Rottoli P, Magi B, Perari MG, Liberatori S, Nikiforakis N, Bargagli E, et al. Cytokine
profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis,
pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fib‐
rosis. Proteomics. 2005;5:1423-30.
[60] Shigehara K, Shijubo N, Ohmichi M, Takahashi R, Kon S, Okamura H, et al. IL-12
and IL-18 Are Increased and Stimulate IFN-γ Production in Sarcoid Lungs. The Jour‐
nal of Immunology. 2001;166:642-9.
[61] Katchar K, Eklund A, Grunewald J. Expression of Th1 markers by lung accumulated
T cells in pulmonary sarcoidosis. Journal of Internal Medicine. 2003;254:564- 71.
[62] Nureki S, Miyazaki E, Ando M, Ueno T, Fukami T, Kumamoto T, et al. Circulating
levels of both Th1 and Th2 chemokines are elevated in patients with sarcoidosis. Res‐
piratory Medicine. 2008;102:239-47.
[63] Tsiligianni I, Antoniou KM, Kyriakou D, Tzanakis N, Chrysofakis G, Siafakas NM, et
al. Th1/Th2 cytokine pattern in bronchoalveolar lavage fluid and induced sputum in
pulmonary sarcoidosis. BMC Pulmonary Medicine. 2005;5:8-13.
[64] Sobiecka M, Kus J, Demkow U, Filewska M, Jozwik A, Radwan-Rohrenschef P, et al.
Induced sputum in patients with interstitial lung disease: a non-invasive surrogate
for certain parameters in bronchoalveolar lavage fluid. Journal of Physiology and
Pharmacology. 2008;59(Suppl 6):645-57.
[65] Mroz RM, Korniluk M, Stasiak-Barmuta A, Ossolinska M, Chyczewska E. Increased
levels of Treg cells in bronchoalveolar lavage fluid and induced sputum of patients
with active pulmonary sarcoidosis. European Journal of Medical Research.
2009;14(Suppl 4):165-9.
[66] Mroz MM, Kreiss K, Lezotte DC, Campbell PA, Newman LS. Reexamination of the
blood lymphocyte transformation test in the diagnosis of chronic beryllium disease.
The Journal of Allergy and Clinical Immunology. 1991;88(1):54-60.
[67] Ahmadzai H, Cameron B, Chui JJ, Lloyd A, Wakefield D, Thomas PS. Peripheral
blood responses to specific antigens and CD28 in sarcoidosis. Respiratory Medicine.
2012;106(5):701-9.
[68] Seyhan EC, Günlüo฀lu G, Altin S, Çetinkaya E, Sökücü S, Uzun H, et al. Results of
teanus vaccination in sarcoidosis. Sarcoidosis, Vasculitis & Diffuse Lung Diseases.
2012;29(1):3-10.
[69] Friou GJ. A study of the cutaneous reactions to oidomycin, trichopytin and mumps
skin test antigens in patients with sarcoidosis. Yale Journal of Biology and Medicine.
1952;24:533-9.
Laboratory Investigations and Immunological Testing in Sarcoidosis
http://dx.doi.org/10.5772/55294
225
[70] Jones JV. Development of sensitivity to dinitrochlorobenzene in patients with sarcoi‐
dosis. Clinical and Experimental Immunology. 1967;2:477-87.
[71] Daniele RP, Dauber JH, Rossman MD. Immunologic abnormalities in sarcoidosis.
Annals of Internal Medicine. 1980;92(3):406-16.
[72] Kataria YP, LoBuglio AF, Helentjaris T, Bromberg PA. Phytohemagglutinin (PHA)
skin test in patients with sarcoidosis. American Review of Respiratory Disease.
112(4):575-8.
[73] Gupta D, Chetty M, Kumar N, Aggarwal AN, Jindal SK. Anergy to tuberculin in sar‐
coidosis is not influenced by high prevalence of tuberculin sensitivity in the popula‐
tion. Sarcoidosis, Vasculitis & Diffuse Lung Diseases. 2003;20(1):40-5.
[74] Amicosante M. IGRAs for tuberculosis in sarcoidosis patients: is the immune re‐
sponse to mycobacteria helpful in the differential diagnosis or still a confounding
factor? Sarcoidosis, Vasculitis & Diffuse Lung Diseases. 2011;28(2):85-6.
[75] Gupta D, Kumar S, Aggarwal AN, Verma I, Agarwal R. Interferon gamma release as‐
say (QuantiFERON-TB Gold In Tube) in patients of sarcoidosis from a population
with high prevalence of tuberculosis infection. Sarcoidosis, Vasculitis & Diffuse Lung
Diseases. 2011;28(2):95-101.
[76] Luetkemeyer AF, Charlebois ED, Flores LL, Bangsberg DR, Deeks SG, Martin JN, et
al. Comparison of an interferon-gamma release assay with tuberculin skin testing in
HIV-infected individuals. American Journal of Respiratory and Critical Care Medi‐
cine. 2007;175(7):737-42.
[77] Mori T, Sakatani M, Yamagishi F, Takashima T, Kawabe Y, Nagao K, et al. Specific
detection of tuberculosis infection: an interferon-gamma-based assay using new anti‐
gens. American Journal of Respiratory and Critical Care Medicine. 2004;170(1):59-64.
[78] Iannuzzi MC, Fontana JR. Sarcoidosis: clinical presentation, immunopathogenesis,
and therapeutics. Jorunal of the Aerican Medical Association. 2011;305(4):391-9.
[79] James GD, Williams WJ. 2. Classification of granulomatous disorders: a clinico-
pathological synthesis. In: James GD, Zumla, A., editor. The Granulomatous Disor‐
ders. Cambridge: Cambridge University Press; 1999.
[80] Ezzie ME, Crouser ED. Considering an infectious etiology of sarcoidosis. Clinics in
Dermatology. 2007;25(3):259-66.
[81] Inui N, Suda T, Chida K. Use of the QuantiFERON-TB Gold test in Japanese patients
with sarcoidosis. Respiratory Medicine. 2008;102:313-5.
[82] Hörster R, Kirsten D, Gaede KI, Jafari C, Strassburg A, Greinert U, et al. Antimyco‐
bacterial immune responses in patients with pulmonary sarcoidosis. The Clinical
Respiratory Journal. 2009;3(4):229-38.
Sarcoidosis226
[83] Chen ES, Wahlström J, Song Z, Willett MH, Wikén M, Yung RC, et al. T Cell Re‐
sponses to Mycobacterial Catalase-Peroxidase Profile a Pathogenic Antigen in Sys‐
temic Sarcoidosis. The Journal of Immunology. 2008;181(8784-8796).
[84] Oswald-Richter K, Culver DA, Hawkins C, Hajizadeh R, Abraham S, Shepherd BE, et
al. Cellular Responses to Mycobacterial Antigens Are Present in Bronchoalveolar
Lavage Fluid Used in the Diagnosis of Sarcoidosis. Infection and Immunity.
2009;77(9):3740-8.
[85] Oswald-Richter K, Sato H, Hajizadeh R, Shepherd BE, Sidney J, Sette A, et al. Myco‐
bacterial ESAT-6 and katG are Recognized by Sarcoidosis CD4+ T Cells When Pre‐
sented by the American Sarcoidosis Susceptibility Allele, DRB1*1101. Journal of
Clinical Immunology. 2010;30:157-66.
[86] Oswald-Richter K, Beachboard DC, Zhan X, Gaskill CF, Abrahams S, Jenkins C, et al.
Multiple mycobacterial antigens are targets of the adaptive immune response in pul‐
monary sarcoidosis. Respiratory Research. 2010;11:161.
[87] Drake WP, Dhason MS, Nadaf M, Shepherd BE, Vadivelu S, Hajizadeh R, et al. Cellu‐
lar Recognition of Mycobacterium tuberculosis ESAT-6 and KatG Peptides in Sys‐
temic Sarcoidosis. Infection and Immunity. 2007;75(1):527-30.
[88] Carlisle J, Evans W, Hajizadeh R, Nadaf M, Shepherd B, Ott RD, et al. Multiple My‐
cobacterium antigens induce interferon-γ production for sarcoidosis peripheral
blood mononuclear cells. Clinical and Experimental Immunology. 2007;150:460-8.
[89] Dubaniewicz A, Trzonkowski P, Dubaniewicz-Wybieralska M, Dubaniewicz A,
Singh M, Mýsliwski A. Mycobacterial heat shock protein-induced blood T lympho‐
cytes subsets and cytokine pattern: Comparison of sarcoidosis with tuberculosis and
healthy controls. Respirology. 2007;12:346-54.
[90] Dubaniewicz A. Mycobacterium tuberculosis heat shock proteins and autoimmunity
in sarcoidosis. Autoimmunity Reviews. 2010;9(6):419-24.
[91] 91. Hajizadeh R, Sato H, Carlisle J, Nadaf MT, Evans W, Shepherd BE, et al. Myco‐
bacterium tuberculosis Antigen 85A Induces Th-1 Immune Responses in Systemic
Sarcoidosis. Journal of Clinical Immunology. 2007;27(4):445-54.
[92] Allen SS, Evans W, Carlisle J, Hajizadeh R, Nadaf M, Shepherd BE, et al. Superoxide
dismutase A antigens derived from molecular analysis of sarcoidosis granulomas
elicit systemic Th-1 immune responses. Respiratory Research. 2008;9:36-47.
[93] Oswald-Richter KA, Beachboard DC, Seeley EH, Abraham S, Shepherd BE, Jenkins
CA, et al. Dual Analysis for Mycobacteria and Propionibacteria in Sarcoidosis BAL.
Journal of Clinical Immunology. 2012;32(5):1129-40.
[94] Brincker H, Pedersen NT. Immunohistologic separation of B-cell-positive granulo‐
mas from B-cell-negative granulomas in paraffin-embedded tissues with special ref‐
Laboratory Investigations and Immunological Testing in Sarcoidosis
http://dx.doi.org/10.5772/55294
227
erence to tumor-related sarcoid reactions. Acta Pathologica, Microbiologica et
Immunologica Scandinavica. 1991;99(3):282-90.
[95] Brownell I, Ramírez-Valle F, Sanchez M, Prystowsky S. Evidence for mycobacteria in
sarcoidosis. American Journal of Respiratory Cell and Molecular Biology. 2011;45(5):
899-905.
[96] Richter J, Bartak F, Halova R. Detection of mycobacteria by fluorescent microscopy in
sarcoidosis. In: Levinsky L, Macholda F, editors. 5th International Conference on Sar‐
coidosis; June 16-21, 1969; Prague: University Karlova; 1971. p 83-4.
[97] Ma Y, Gal A, Koss MN. The pathology of pulmonary sarcoidosis: update. Seminars
in Diagnostic Pathology. 2007;24(3):150-61.
[98] Alavi HA, Moscovic EA. Immunolocalization of cell-wall-deficient forms of Myco‐
bacterium tuberculosis complex in sarcoidosis and in sinus histiocytosis of lymph no‐
des draining carcinoma. Histology and Histopathology. 1996;11(3):683-94.
[99] Cantwell ARJ. Histologic observations of variably acid-fast pleomorphic bacteria in
systemic sarcoidosis: a report of 3 cases. Growth. 1982;46(2):113-25.
[100] Kon OM, du Bois RM. Mycobacteria and sarcoidosis. Thorax. 1997;52(Supp 3):S47-
S51.
[101] Brown ST, Brett I, Almenoff PL, Lesser M, Terrin M, Teirstein AS. Recovery of cell
wall-deficient organisms does not distinguish between patients with sarcoidosis and
control subjects. Chest. 2003;123(413-417).
[102] Almenoff PL, Johnson A, Lesser M, Mattman LH. Growth of acid fast L forms from
the blood of patients with sarcoidosis. Thorax. 1996;51(5):530-3.
[103] Moscovic EA. Sarcoidosis and mycobacterial L-forms. A critical reappraisal of pleo‐
morphic chromogenic bodies (Hamazaki corpuscles) in lymph nodes. Pathology An‐
nual. 1978;13(Pt 2):69-164.
[104] el-Zaatari FA, Naser SA, Markesich DC, Kalter DC, Engstand L, Graham DY. Identi‐
fication of Mycobacterium avium complex in sarcoidosis. Journal of Clinical Microbi‐
ology. 1996;34(9):2240-5.
[105] Onwuamaegbu ME, Belcher RA, Soare C. Cell wall-deficient bacteria as a cause of in‐
fections: a review of the clinical significance. The Journal of International Medical Re‐
search. 2005;33(1):1-20.
[106] Hess CL, Wolock BS, Murphy MS. Mycobacterium marinum infections of the upper
extremity. Plastic and Reconstructive Surgery. 2005;115(3):55e-9e.
[107] Moling O, Sechi LA, Zanetti S, Seebacher C, Rossi P, Rimenti G, et al. Mycobacterium
marinum, a further infectious agent associated with sarcoidosis: the polyetiology hy‐
pothesis. Scandinavian Journal of Infectious Diseases. 2006;38(2):148-52.
Sarcoidosis228
[108] Saboor SA, Johnson NM, McFadden J. Detection of mycobacterial DNA in sarcoido‐
sis and tuberculosis with polymerase chain reaction. The Lancet. 1992;339(1012-1015).
[109] Fidler HM, Rook GA, Johnson NM, McFadden J. Mycobacterium tuberculosis DNA
in tissue affected by sarcoidosis. British Medical Journal. 1993;306(6877):546-9.
[110] Grosser M, Luther T, Muller J, Schuppler M, Brickhardt J, Matthiessen W, et al. De‐
tection of M. tuberculosis DNA in Sarcoidosis: correlation with T-cell response. Labo‐
ratory Investigation. 1999;79(7):775-84.
[111] Klemen H, Husain AN, Cagle PT, Garrity ER, Popper HH. Mycobacterial DNA in re‐
current sarcoidosis in the transplanted lung- a PCR-based study on four cases. Virch‐
ows Archiv. 2000;436(4):365-9.
[112] Drake WP, Pei Z, Pride DT, Collins RD, Cover TL, Blaser MJ. Molecular analysis of
sarcoidosis tissues for mycobacterium species DNA. Emerging Infectious Diseases.
2002;8(11):1334-41.
[113] Eishi Y, Suga M, Ishige I, Kobayashi D, Yamada T, Takemura T, et al. Quantitative
analysis of mycobacterial and propionibacterial DNA in lymph nodes of Japanese
and European patients with sarcoidosis. Journal of Clinical Microbiology. 2002;40(1):
198-204.
[114] Svendsen CB, Milman N, Rasmussen EM, Thomsen VØ, Andersen CB, Krogfelt KA.
The continuing search for Mycobacterium tuberculosis involvement in sarcoidosis: a
study on archival biopsy specimens. The Clinical Respiratory Journal. 2011;5(2):
99-104.
[115] Lisby G, Milman N, Jacobsen GK. Search for Mycobacterium paratuberculosis DNA
in tissue from patients with sarcoidosis by enzymatic gene amplification. Acta Patho‐
logica, Microbiologica et Immunologica Scandinavica. 1993;101(11):876-8.
[116] Vokurka M, Lecoissier D, du Bois RM, Wallaert B, Kambouchner M, Tazi A, et al.
Absence of DNA from mycobacteria of the M, tuberculosis complex in sarcoidosis.
American Journal of Respiratory and Critical Care Medicine. 1997;156(1000-1003).
[117] Gupta D, Agarwal R, Agarwal AN, Jindal SK. Molecular evidence for the role of my‐
cobacteria in sarcoidosis: A meta-analysis. European Respiratory Journal. 2007;30(3):
508-16.
[118] Milman N. From Mycobacteria to Sarcoidosis - Is the Gate Still Open? Respiration.
2006;73:14-5.
[119] Abe C, Iwai K, Mikami R, Hosoda Y. Frequent isolation of Propionibacterium acnes
from sarcoidosis lymph nodes. Zentralbl Bakteriol Mikrobiol Hyg A. 1984;256(4):
541-7.
[120] Ebe Y, Ikushima S, Yamaguchi T, Kohno K, Azuma A, Sato K, et al. Proliferative re‐
sponse of peripheral blood mononuclear cells and levels of antibody to recombinant
Laboratory Investigations and Immunological Testing in Sarcoidosis
http://dx.doi.org/10.5772/55294
229
protein from Propionibacterium acnes DNA expression library in Japanese patients
with sarcoidosis. Sarcoidosis, Vasculitis & Diffuse Lung Diseases. 2000;17(3):256-65.
[121] Ishige I, Usui Y, Takemura T, Eishi Y. Quantitative PCR of mycobacterial and propio‐
nibacterial DNA in lymph nodes of Japanese patients with sarcoidosis. The Lancet.
1999;354(9173):120-3.
[122] Gazouli M, Ikonomopoulos J, Trigidou R, Foteinou M, Kittas C, Gorgoulis V. Assess‐
ment of mycobacterial, propionibacterial, and human herpesvirus 8 DNA in tissues
of Greek patients with sarcoidosis. Journal of Clinical Microbiology. 2002;40:3060-3.
[123] Yamada T, Eishi Y, Ikeda S, Ishige I, Suzuki T, Takemura T, et al. In situ localization
of Propionibacterium acnes DNA in lymph nodes from sarcoidosis patients by signal
amplification with catalysed reporter deposition. The Journal of Pathology.
2002;198(4):541-7.
[124] Ishige I, Eishi Y, Takemura T, Kobayashi I, Nakata K, Tanaka I, et al. Propionibacteri‐
um acnes is the most common bacterium commensal in peripheral lung tissue and
mediastinal lymph nodes from subjects without sarcoidosis. Sarcoidosis, Vasculitis
and Diffuse Lung Diseases. 2005;22(1):33-42.
[125] Newman LS, Rose CS, Maier LA. Sarcoidosis. The New England Journal of Medicine.
1997;336(17):1224-34.
[126] Yamada M, Fujimoto, F. Lymphocyte transformation using Mitsuda antigen (lepro‐
min). The Journal of Dermatology. 1975;2(4):175-8.
[127] Proença NG. Interpretation of the Mitsuda and Kveim tests in the differential diagno‐
sis of tuberculoid hanseniasis and cutaneous sarcoidosis. [Article in Portuguese]. Me‐
dicina cutánea ibero-latino-americana. 1989;17(3):163-5.
[128] Rossman MD, Kreider ME. Is chronic beryllium disease sarcoidosis of known etiolo‐
gy? Sarcoidosis, Vasculitis & Diffuse Lung Diseases. 2003;20:104-9.
[129] Newman KL, Newman LS. Occupational causes of sarcoidosis. Current Opinion in
Allergy and Clinical Immunology. 2012;12(2):145-50.
[130] Pott GB, Palmer BE, Sullivan AK, Silviera L, Maier LA, Newman LS, et al. Frequency
of beryllium-specific, TH1-type cytokine-expressing CD4+ T cells in patients with
beryllium-induced disease. Journal of Allergy and Clinical Immunology. 2005;115(5):
1036-42.
[131] Tinkle SS, Kittle LA, Schumacher BA, Newman LS. Beryllium induces IL-2 and IFN-
gamma in berylliosis. Journal of Immunology. 1997;158(1):518-26.
[132] Glazer CS, Newman LS. 15. Beryllium as a model for sarcoidosis. In: Baughman RP,
editor. Lung Biology in Health and Disease- Sarcoidosis. New York: Taylor and Fran‐
cis Group; 2006.
Sarcoidosis230
[133] Siltzbach LE. The Kveim test in sarcoidosis: a study of 750 patients. Journal of the
American Medical Association. 1961;178:476-82.
[134] Teirstein AS. The Kveim-Siltzbach test. Clinics in Dermatology. 1986;4(4):154-64.
[135] Kveim A. En ny og spesifikk kutan-reaksjon ved Boeck's sarcoid. Nordisk medicin.
1941;9:169-72.
[136] Parrish S, Turner JF. Diagnosis of Sarcoidosis. Disease-a-Month. 2009;55(11):693-703.
[137] Holter JF, Park, H.K., Sjoerdsma, K.W., Kataria, Y.P. Nonviable autologous bron‐
choalveolar lavage cell preparations induce intradermal epithelioid cell granulomas
in sarcoidosis patients. American Review of Respiratory Disease. 1992;145(4 Pt 1):
864-71.
[138] Gaede KI, Kataria YP, Mamat U, Müller-Quernheim J. Analysis of differentially regu‐
lated mRNAs in monocytic cells induced by in vitro stimulation with Kveim-Siltz‐
bach test reagent. Experimental Lung Research. 2004;30(3):181-92.
[139] Siltzbach LE, editor. An international Kveim test study in sarcoidosis. Proceedings of
the Fourth International Conference on sarcoidosis; 1967; Paris: Mason.
[140] Mishra BB, Poulter LW, Janossy G, Sherlock S, James DG. The Kveim-Siltzbach gran‐
uloma. A model for sarcoid granuloma formation. Annals of the New York Academy
of Sciences. 1986;465(164-75.).
[141] de Silva RN, Will RG. Moratorium on Kveim test. The Lancet. 1993;342(8864):173.
[142] Williams WJ, Price CD, Pugh A, Dighero M. In vitro (KMIF) Test. Zeitschrift für Erk‐
rankungen der Atmungsorgane. 1977;149(2):226-30.
[143] Lyons DJ, Mitchell EB, Mitchell DN. Sarcoidosis: in search of Kveim reactivity in vi‐
tro. Biomedicine and Pharmacotherapy. 1991;45(4-5):187-92.
[144] Cowling DC, Quaglino D, Barrett PKM. Effect of Kveim Antigen and Old Tuberculin
on Lymphocytes in Culture from Sarcoid Patients. British Medical Journal.
1964;1(5396):1481-2.
[145] Kurti V, Mankiewicz E. In vitro study of macrophages from patients with sarcoido‐
sis. Canadian Medical Association Journal. 1972;107(6):509-15.
[146] Izumi T, Nilsson BS, Ripe E. In vitro lymphocyte reactivity to different Kveim prepa‐
rations in patients with sarcoidosis. Scandinavian Journal of Respiratory Diseases.
1973;54(2):123-7.
[147] Lindahl M, Andersson O, Ripe E, Holm G. Stimulation of Bronchoalveolar (BAL) and
blood lymphocytes by Kveim antigen, Tuberculin, and Concanavalin A in sarcoido‐
sis. British Diseases of the Chest. 1988;82(4):386-93.
Laboratory Investigations and Immunological Testing in Sarcoidosis
http://dx.doi.org/10.5772/55294
231
[148] Chase MW, Siltzbach LE, editor. Concentration of the active principle responsible for
the Kveim reaction. Proceedings of the 4th International Conference on Sarcoidosis;
1967; Paris: Mason.
[149] James GD, Williams WJ. Kveim-Siltzbach Test Revisited. Sarcoidosis. 1991;8(1):6-9.
[150] Klein JT, Horn TD, Forman JD, Silver RF, Teirstein AS, Moller DR. Selection of Oligo‐
clonal Vβ-specific T Cells in the Intradermal Response to Kveim-Siltzbach Reagent in
Individuals with Sarcoidosis. The Journal of Immunology. 1995;154:1450-60.
[151] Moller DR, Konishi K, Kirby M, Balbi B, Crystal RG. Bias toward use of a specific T
cell receptor beta-chain variable region in a subgroup of individuals with sarcoidosis.
Journal of Clinical Investigation. 1988;82(4):1183-91.
[152] Lyons DJ, Donald S, Mitchell DN, Asherson GL. Chemical Inactivation of the Kveim
Reagent. Respiration. 1992;59:22-6.
[153] Song Z, Marzilli L, Greenlee BM, Chen ES, Silver RF, Askin FB, et al. Mycobacterial
catalase–peroxidase is a tissue antigen and target of the adaptive immune response
in systemic sarcoidosis. The Journal of Experimental Medicine. 2005;201(5):755-67.
[154] Studdy PR, Bird R. Serum angiotensin converting enzyme in sarcoidosis - its value in
present clinical practice. Annals of Clinical Biochemistry. 1989;26:13-8.
[155] Lieberman J, Zakria F. Effect of captopril and enalapril medication on the serum ACE
test for sarcoidosis. Sarcoidosis. 1989;6(2):118-23.
[156] Rohrbach MS, DeRemee RA. Age dependence of serum angiotensin-converting en‐
zyme activity. The Lancet. 1979;2(8135):196.
[157] Lieberman J. Elevation of serum angiotensin-converting-enzyme (ACE) level in sar‐
coidosis. The American Journal of Medicine. 1975;59(3):365-72.
[158] Studdy P, Bird R, James DG. Serum angiotensin-converting enzyme (SACE) in sar‐
coidosis and other granulomatous disorders. The Lancet. 1978;2(8104-5):1331-4.
[159] Pertschuk LP, Silverstein E, Friedland J. Immunohistologic diagnosis of sarcoidosis.
Detection of angiotensin-converting enzyme in sarcoid granulomas. American Jour‐
nal of Clinical Pathology. 1981;75(3):350-4.
[160] Loddenkemper R, Kloppenborg A, Schoenfeld N, Grosser H, Costabel U. Clinical
findings in 715 patients with newly detected pulmonary sarcoidosis--results of a co‐
operative study in former West Germany and Switzerland. WATL Study Group.
Wissenschaftliche Arbeitsgemeinschaft für die Therapie von Lungenkrankheitan.
Sarcoidosis, Vasculitis & Diffuse Lung Diseases. 1998;15(2):178-82.
[161] Lieberman J, Nosal A, Schlessner A, Sastre-Foken A. Serum angiotensin-converting
enzyme for diagnosis and therapeutic evaluation of sarcoidosis. American Review of
Respiratory Disease. 1979;120(2):329-35.
Sarcoidosis232
[162] Gronhagen-Riska C, Kurppa K, Fyhrquist F, Selroos O. Angiotensin-converting en‐
zyme and lysozyme in silicosis and asbestosis. Scandinavian Journal of Respiratory
Diseases. 1978;59(4):228-31.
[163] Newman LS, Orton R, Kreiss K. Serum angiotensin converting enzyme activity in
chronic beryllium disease. The American Review of Respiratory Disease. 1992;146(1):
39-42.
[164] Davies SF, Rohrbach MS, Thelen V, Kuritsky J, Gruninger R, Simpson ML, et al. Ele‐
vated serum angiotensin-converting enzyme (SACE) activity in acute pulmonary his‐
toplasmosis. Chest. 1984;85(3):307-10.
[165] Gupta SK, Chakraborty M, Mitra K. Serum angiotensin converting enzyme in respi‐
ratory diseases. The Indian Journal of Chest Diseases and Allied Sciences. 1992;34(1):
19-24.
[166] Brice EA, Friedlander W, Bateman ED, Kirsch RE. Serum angiotensin-converting en‐
zyme activity, concentration, and specific activity in granulomatous interstitial lung
disease, tuberculosis, and COPD. Chest. 1995;107(3):706-10.
[167] Lieberman J, Sastre A. Serum angiotensin-converting enzyme: elevations in diabetes
mellitus. Annals of Internal Medicine. 1980;93(6):825-6.
[168] Smallridge RC, Rogers J, Verma PS. Serum angiotensin-converting enzyme: altera‐
tions in hyperthyroidism, hypothyroidism and subacute thyroiditis. Journal of the
American Medical Association. 1983;250:2489-93.
[169] Lieberman J, Beutler E. Elevation of serum angiotensin-converting enzyme in Gauch‐
er's disease. The New England Journal of Medicine. 1976;294(26):1442-4.
[170] Biller H, Ruprecht B, Gaede KI, Müller-Quernheim J, Zissel G. Gene polymorphisms
of ACE and the angiotensin receptor AT2R1 influence serum ACE levels in sarcoido‐
sis. Sarcoidosis, Vasculitis & Diffuse Lung Diseases. 2009;26(2):139-46.
[171] Kruit A, Grutters JC, Gerritsen WB, Kos S, Wodzig WK, van den Bosch JM, et al. ACE
I/D-corrected Z-scores to identify normal and elevated ACE activity in sarcoidosis.
Respiratory Medicine. 2007;101(3):510-5.
[172] Allen RK, Pierce RJ, Barter CE. Angiotensin-converting enzyme in bronchoalveolar
lavage fluid in sarcoidosis. . Sarcoidosis. 1992;9(1):54-9.
[173] Tahmoush AJ, Amir MS, Connor WW, Farry JK, Didato S, Ulhoa-Cintra A, et al. CSF-
ACE activity in probable CNS neurosarcoidosis. Sarcoidosis, Vasculitis & Diffuse
Lung Diseases. 2002;19(3):191-7.
[174] Miyoshi S HH, Kadowaki T, Hamaguchi N, Ito R, Irifune K, et al. Comparative eval‐
uation of serum markers in pulmonary sarcoidosis. Chest. 2010;137(6):1391-7.
[175] Tomita H, Sato S, Matsuda R, Sugiura Y, Kawaguchi H, Niimi T, et al. Serum lyso‐
zyme levels and clinical features of sarcoidosis. Lung. 1999;177(3):161-7.
Laboratory Investigations and Immunological Testing in Sarcoidosis
http://dx.doi.org/10.5772/55294
233
[176] Pascual RS, Gee JB, Finch SC. Usefulness of serum lysozyme measurement in diagno‐
sis and evaluation of sarcoidosis. The New England Journal of Medicine.
1973;289(20):1074-6.
[177] Klockars M, Selroos O. Immunohistochemical demonstration of lysozyme in the
lymph nodes and Kveim reaction papules in sarcoidosis. Acta Pathologica et Micro‐
biologica Scandinavica, Section A. 1977;85A(2):169-73.
[178] Prior C, Barbee RA, Evans PM, Townsend PJ, Primett ZS, Fyhrquist F, et al. Lavage
versus serum measurements of lysozyme, angiotensin converting enzyme and other
inflammatory markers in pulmonary sarcoidosis. European Respiratory Journal.
1990;3(10):1146-54.
[179] Klockars M, Pettersson T, Weber TH, Froseth B, Selroos O. Angiotensin-converting
enzyme, lysozyme, beta-2-microglobulin and adenosine deaminase in sarcoidosis.
Archivio Monaldi. 1984;39(5-6):345-56.
[180] Homolka J, Lorenz J, Zuchold HD, Müller-Quernheim J. Evaluation of soluble CD 14
and neopterin as serum parameters of the inflammatory activity of pulmonary sar‐
coidosis. The Clinical Investigator. 1992;70(10):909-16.
[181] Eklund A, Blaschke E. Elevated serum neopterin levels in sarcoidosis. Lung.
1986;164(6):325-32.
[182] Lacronique J, Auzeby A, Valeyre D, Traore BM, Barbosa ML, Soler P, et al. Urinary
neopterin in pulmonary sarcoidosis. Relationship to clinical and biologic assessment
of the disease. American Review of Respiratory Disease. 1989;139(6):1474-8.
[183] Kollert F, Geck, B, Suchy R, Jörres RA, Arzt M, Heidinger D, et al. The impact of gas
exchange measurement during exercise in pulmonary sarcoidosis. Respiratory Medi‐
cine. 2011;105(1):122-9.
[184] Blaschke E, Eklund A, Persson U. Relationship between serum neopterin and lym‐
phocytic alveolitis in sarcoidosis. Sarcoidosis. 1988;5(1):25-30.
[185] Planck A, Eklund A, Grunewald J. Markers of activity in clinically recovered human
leukocyte antigen-DR17-positive sarcoidosis patients. European Respiratory Journal.
2003;21(1):52-7.
[186] Prior C, Frank A, Fuchs D, Hausen A, Judmaier G, Reibnegger G, et al. Urinary neo‐
pterin excretion in pulmonary sarcoidosis: correlation to clinical course of the dis‐
ease. Clinica Chimica Acta. 1988;177(3):211-20.
[187] Bargagli E, Maggiorelli C, Rottoli P. Human Chitotriosidase: a potential new marker
of sarcoidosis severity. Respiration. 2008;76(234-38.).
[188] Boot RG, Hollak CE, Verhoek M, Alberts C, Jonkers RE, Aerts JM. Plasma chitotriosi‐
dase and CCL18 as surrogate markers for granulomatous macrophages in sarcoido‐
sis. Clinica Chimica Acta. 2010;411(1-2):31-6.
Sarcoidosis234
[189] Korolenko TA, Zhanaeva SY, Falameeva OV, Kaledin VI, Filyushina EE, Buzueva II,
et al. Chitotriosidase as a marker of macrophage stimulation. Bulletin of Experimen‐
tal Biology and Medicine. 2000;130(10):948-50.
[190] Bargagli E, Bianchi N, Margollicci M, Olivieri C, Luddi A, Coviello G, et al. Chitotrio‐
sidase and soluble IL-2 receptor: comparison of two markers of sarcoidosis severity.
Scandinavian Journal of Clinical and Laboratory Investigation. 2008;68(6):479-83.
[191] Bargagli E, Margollicci M, Perrone A, Luddi A, Perari MG, Bianchi N, et. Chitotriosi‐
dase analysis in bronchoalveolar lavage of patients with sarcoidosis. Sarcoidosis,
Vasculitis & Diffuse Lung Diseases. 2007;24(1):59-64.
[192] Chen ES, Song Z, Willett MH, Heine S, Yung RC, Liu MC, et al. Serum Amyloid A
Regulates Granulomatous Inflammation in Sarcoidosis through Toll-like Receptor-2.
American Journal of Respiratory and Critical Care Medicine. 2010;181:360-73.
[193] Albera C, Mabritto I, Ghio P, Solidoro P, Marchetti L, Pozzi E. Adenosine deaminase
activity and fibronectin levels in bronchoalveolar lavage fluid in sarcoidosis and tu‐
berculosis. Sarcoidosis. 1993;10(1):18-25.
[194] Wetzel E, Müller-Quernheim J, Lorenz J. [Serum adenosine deaminase as a parame‐
ter for activity in sarcoidosis]. [Article in German]. Pneumologie. 1999;53(7):323-8.
[195] Sofia M, Mormile M, Faraone S, Alifano M, Carratù P, Carratù L. Endothelin-1 excre‐
tion in urine in active pulmonary sarcoidosis and in other interstitial lung diseases.
Sarcoidosis. 1995;12(2):118-23.
[196] Terashita K, Kato S, Sata M, Inoue S, Nakamura H, Tomoike H. Increased endothe‐
lin-1 levels of BAL fluid in patients with pulmonary sarcoidosis. Respirology.
2006;11(2):145-51.
[197] Letizia C, Danese A, Reale MG, Caliumi C, Delfini E, Subioli S, et al. Plasma levels of
endothelin-1 increase in patients with sarcoidosis and fall after disease remission.
Panminerva Medica. 2001;43(4):257-61.
[198] Peros-Golubicić T, Ivicević A, Bekić A, Alilović M, Tekavec-Trkanjec J, Smojver-Jezek
S. Lung lavage neutrophils, neutrophil elastase and albumin in the prognosis of pul‐
monary sarcoidosis. Collegium Antropologicum. 2001;25(1):349-55.
[199] O'Connor C, Odlum C, Van Breda A, Power C, Fitzgerald MX. Collagenase and fi‐
bronectin in bronchoalveolar lavage fluid in patients with sarcoidosis. Thorax.
1988;43(5):393-400.
[200] Magi B, Bini L, Perari MG, Fossi A, Sanchez JC, Hochstrasser D, et al. Bronchoalveo‐
lar lavage fluid protein composition in patients with sarcoidosis and idiopathic pul‐
monary fibrosis: a two-dimensional electrophoretic study. Electrophoresis.
2002;23(19):3434-44.
Laboratory Investigations and Immunological Testing in Sarcoidosis
http://dx.doi.org/10.5772/55294
235
[201] Sabounchi-Schütt F, Aström J, Hellman U, Eklund A, Grunewald J. Changes in bron‐
choalveolar lavage fluid proteins in sarcoidosis: a proteomics approach. European
Respiratory Journal. 2003;21(3):414-20.
[202] Sabounchi-Schütt F, Mikko M, Eklund A, Grunewald J, Aström J. Serum protein pat‐
tern in sarcoidosis analysed by a proteomics approach. Sarcoidosis, Vasculitis & Dif‐
fuse Lung Diseases. 2004;21(3):182-90.
[203] Silva E, Bourin S, Sabounchi-Schütt F, Laurin Y, Barker E, Newman L, et al. A quanti‐
tative proteomic analysis of soluble bronchoalveolar fluid proteins from patients
with sarcoidosis and chronic beryllium disease. Sarcoidosis, Vasculitis & Diffuse
Lung Diseases. 2007;24(1):24-32.
[204] Bons JA, Drent M, Bouwman FG, Mariman EC, van Dieijen-Visser MP, Wodzig WK.
Potential biomarkers for diagnosis of sarcoidosis using proteomics in serum. Respira‐
tory Medicine. 2007;101(8):1687-95.
[205] Kriegova E, Melle C, Kolek V, Hutyrova B, Mrazek F, Bleul A, et al. Protein profiles
of bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis. American
Journal of Respiratory and Critical Care Medicine. 2006;173(10):1145-54.
[206] Moodley YP, Chetty R, Lalloo UG. Nitric oxide levels in exhaled air and inducible
nitric oxide synthase immunolocalization in pulmonary sarcoidosis. European Respi‐
ratory Journal. 1999;14(4):822-7.
[207] Wilsher ML, Fergusson W, Milne D, Wells AU. Exhaled nitric oxide in sarcoidosis.
Thorax. 2005;60(11):967-70.
[208] Choi J, Hoffman LA, Sethi JM, Zullo TG, Gibson KF. Multiple flow rates measure‐
ment of exhaled nitric oxide in patients with sarcoidosis: a pilot feasibility study. Sar‐
coidosis, Vasculitis & Diffuse Lung Diseases. 2009;26(2):98-109.
[209] Ciarleglio G, Refini RM, Pieroni MG, Martino VA, Bargagli E, Rottoli P, et al. Exhaled
carbon monoxide in sarcoidosis. Sarcoidosis, Vasculitis & Diffuse Lung Diseases.
2008;25(1):46-50.
[210] Kharitonov SA, Barnes PJ. Exhaled Markers of Pulmonary Disease. American Journal
of Respiratory and Critical Care Medicine. 2001;163:1693-722.
[211] Horváth I, Hunt J, Barnes PJ. Exhaled breath condensate: methodological recommen‐
dations and unresolved questions. European Respiratory Journal. 2005;26(3):523-48.
[212] Mutlu GM, Garey KW, Robbins RA, Danziger LH, Rubinstein I. Collection and Anal‐
ysis of Exhaled Breath Condensate in Humans. American Journal of Respiratory and
Critical Care Medicine. 2001;164:731-7.
[213] Jackson AS, Sandrini A, Campbell C, Chow S, Thomas PS, Yates DH. Comparison of
Biomarkers in Exhaled Breath Condensate and Bronchoalveolar Lavage. American
Journal of Respiratory and Critical Care Medicine. 2007;175(222-227).
Sarcoidosis236
[214] Rożyi A, Czerniawska J, Stępniewska A, Woźbińska B, Goljan A, Puścińska E, et al.
Inflammatory markers in the exhaled breath condensate of patients with pulmonary
sarcoidosis. Journal of Physiology and Pharmacology. 2006;57(4):335-40.
[215] Nayeri F, Millinger E, Nilsson I, Zetterström, Brudin L, Forsberg P. Exhaled breath
condensate and serum levels of hepatocyte growth factor in pneumonia. Respiratory
Medicine. 2002;96(2):115-9.
[216] Piotrowski WJ, Kurmanowska Z, Antczak A, Marczak J, Górski P. Hepatocyte
growth factor in exhaled breath and BAL fluid in sarcoidosis. Pneumonologia i aler‐
gologia polska. 2010;78(3):187-91.
[217] Kowalska A, Puścińska E, Czerniawska J, Goljan-Geremek A, Czystowska M, Roży
A, et al. Markers of fibrosis and inflammation in exhaled breathcondensate (EBC)
and bronchoalveolar lavage fluid (BALF) of patients with pulmonary sarcoidosis- a
pilot study [Polish]. Pneumonologia i alergologia polska. 2010;78(5):356-62.
[218] Psathakis K, Papatheodorou G, Plataki M, Panagou P, Loukides S, Siafakas NM, et al.
8-Isoprostane, a Marker of Oxidative Stress, Is Increased in the Expired Breath Con‐
densate of Patients With Pulmonary Sarcoidosis. Chest. 2004;125:1005-11.
[219] Antczak A, Piotrowski W, Marczak J, Ciebiada M, Gorski P, Barnes PJ. Correlation
between eicosanoids in bronchoalveolar lavage fluid and in exhaled breath conden‐
sate. Disease Markers. 2011;30(5):213-20.
[220] Piotrowski WJ, Kurmanowska Z, Antczak A, Marczak J, Górski P. Exhaled 8-isopros‐
tane as a prognostic marker in sarcoidois. A short term follow up. BMC Pulmonary
Medicine. 2010;10:23-9.
[221] Piotrowski WJ, Antczak A, Marczak J, Nawrocka A, Kurmanowska Z, Górski P. Eico‐
sanoids in exhaled breath condensate and BAL Fluid of patients with Sarcoidosis.
Chest. 2007;132:589-96.
[222] Kwiatkowska S, Luczynska M., Grzelewska-Rzymowska I, Nowak D, Zieba M. Com‐
parison of oxidative stress markers in exhaled breath condensate and in serum of pa‐
tients with tuberculosis and sarcoidosis. [Polish]. Polski Merkuriusz Lekarski.
2005;19(109):37-40.
Laboratory Investigations and Immunological Testing in Sarcoidosis
http://dx.doi.org/10.5772/55294
237

